Expression and purification of proteins using calpain tag
By fusing the myostatin tag with the target protein, the problem of extracting the target protein from animals, plants, or microorganisms has been solved, achieving efficient expression and purification while reducing costs.
Patent Information
- Application Number
- CN202080027482.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-03-31
- Filing Date
- 2020-04-01
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2040-04-01
AI Technical Summary
Existing technologies for expressing and purifying target proteins from animals, plants, or microorganisms suffer from difficulties in extracting target proteins and low efficiency, especially when they are not obtained through secretion, making it difficult to achieve high-purity and high-efficiency protein separation.
By employing a method of fusing a myostatin tag with a target protein, a fusion protein containing both a myostatin tag and a target protein is prepared. Then, high expression, water solubility, and purification of the target protein are achieved through calcium precipitation and peptide decomposition by hydrolytic enzymes, thereby reducing the cost of protein materials and drugs.
It achieves efficient expression and water solubility of the target protein, and simplifies the purification process by using calcium precipitation, thereby improving purity and reducing costs.
Smart Images

Figure CN114040923B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a method for expressing, solubilizing and purifying a protein using a calsequestrin-tag, and provides a fusion protein comprising a calsequestrin-tag and a target protein, a nucleic acid comprising a nucleotide sequence encoding the fusion protein, an expression vector comprising the nucleic acid, a cell transformed with the expression vector, and a method for expressing, solubilizing and purifying a target protein using a calsequestrin-tag. The present invention increases the expression and solubilization of proteins widely used in medicines and cosmetics using a calsequestrin-tag, and makes the protein easily separated by calcium, thereby reducing the cost of protein materials and medicines. Background Art
[0002] Recently, with the development of genetic engineering and biology, there are many attempts to mass produce or obtain specific proteins for various industries and the treatment of diseases. Therefore, protein combination technology, mass production technology and purification technology for obtaining the desired protein are vigorously developed. Generally, the target protein required by humans can be expressed and produced by culturing cells transformed with vectors expressing it. Depending on the situation, this protein can be expressed in eukaryotic cells, prokaryotic cells, etc., and in special cases, it can be expressed in transgenic plants or transgenic animals. For example, an attempt is made to express it in transgenic animals that secrete milk, and a method of obtaining the target protein through the milk of transgenic animals is used. In this case, the protein can be separated and purified from cell culture or milk.
[0003] In the case of expressing proteins in plants, animals or microorganisms without a separate method for obtaining target proteins through secretion, a process of extracting proteins from storage organs or cells is first required. This operation of obtaining target proteins from transformed cells is not easy. Therefore, in order to easily obtain, a method of recombining the target protein into a form containing a tag rather than a natural type is widely used. The method of using tags for purification is one of the methods that shows very high efficiency in various protein purification technologies. The tags used in this case are roughly divided into peptide tags and protein tags. Peptide tags are composed of short amino acids, and representative ones are histidine tags (his-tag, histidine-tag), especially, hexahistidine tags (hexahistidine tag, His6-tag) are widely used. Histidine peptides have a specific chemical affinity with nickel, and fusion proteins containing corresponding tags can be purified with high purity by a column containing nickel. Protein tags are tags that contain corresponding domains in order to utilize the characteristics of the domains of proteins that bind to specific components. Representative ones are glutathione S transferase tags (GST-tag, Glutathione S-transferase-tag). The glutathione S-transferase tag can be purified at high purity by passing through a column of a glutathione-immobilized medium, which is a substrate of glutathione S-transferase.
[0004] Therefore, the present inventors have made efforts to develop a new tag to facilitate acquisition of the target protein, and as a result, have confirmed that when the calretinin tag is fused to the target protein, the target protein can be easily expressed, solubilized in water, and purified, thereby completing the present invention.
[0005] Existing Literature
[0006] Korean Patent Publication No. 10-2014-0026781 Summary of the invention
[0007] Technical issues
[0008] The object of the present invention is to provide a fusion protein comprising a calpain tag and a target protein.
[0009] Another object of the present invention is to provide a nucleic acid comprising a nucleotide sequence encoding the above fusion protein and an expression vector comprising the above nucleic acid. Figure 1 A schematic diagram showing the recombinant expression vector of the present invention.
[0010] Another object of the present invention is to provide cells transformed with the above expression vector.
[0011] Another object of the present invention is to provide a method for expressing and purifying a target protein using a calpain tag. Figure 2 An example of the method for expressing and purifying the target protein of the present invention is shown.
[0012] Technical Solution
[0013] The present invention relates to a fusion protein comprising a calretinin tag and a target protein for improving the expression and water solubilization of the target protein.
[0014] The calpain tag may be encoded by amino acids consisting of SEQ ID NO:1 or SEQ ID NO:2.
[0015] The above-mentioned calretinin tag may be encoded by a nucleotide sequence consisting of SEQ ID NO:3 or SEQ ID NO:4.
[0016] The calpain tag and the target protein can be fused via a hydrolase-degradable peptide consisting of an amino acid sequence, wherein the amino acid sequence is selected from the group consisting of SEQ ID NO: 5 to SEQ ID NO: 8.
[0017] The present invention is characterized in that the target protein is selected from the group consisting of high molecular weight proteins, glycoproteins, cytokines, growth factors, blood products, vaccines, hormones, enzymes and antibodies. For example, the target protein may be selected from interleukin-2, blood factor VII, blood factor VIII, blood factor IX, immunoglobulin, horseradish peroxidase (HRP), cytokine, α-interferon, β-interferon, γ-interferon, colony stimulating factor (GM-CSF), human fibronectin extra domain B (EBD), bone morphogenetic protein (BMP), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), nerve growth factor (NGF), epidermal growth factor (EGF), insulin-like growth factor (IGF), transforming growth factor-α and transforming growth factor-β (TGF-α, -β), brain-derived neutrophic factor (BNF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), nerve growth factor (NGF), epidermal growth factor (EGF), insulin-like growth factor (IGF), transforming growth factor-α and transforming growth factor-β (TGF-α, -β), brain-derived neutrophic factor (BNF), and fibroblast growth factor (FGF). BDNF), platelet-derived growth factor (PDGF), placental growth factor (PIGF), hepatocyte growth factor (HGF), fibroblast growth factor 1 and 2 (FGF-1,-2), keratinocyte growth factor (KGF), glucagon-like peptide-1 (GLP-1), exendin, somatostatin, luteinizing hormone-releasing hormone (LHRH), adrenocorticotropic hormone, growth hormone-releasing hormone, oxytocin, thymosin alpha-1, corticotropin-releasing factor, calcitonin, bivalirudin, vasopressin, phospholipase activating protein (PLAP), insulin, tumor necrosis factor (TNF), follicle-stimulating hormone, thyroid-stimulating hormone, antidiuretic hormone, pigment hormone, parathyroid hormone, luteinizing hormone, calcitonin gene related peptide (Calcitonin Gene Related Peptide, CGPR), enkephalin, somatomedin, erythropoietin, hypothalamic secretory factor, prolactin, chronic gonadotropin, tissue plasminogen activator, growth hormone releasing peptide (GHPR), thymic humoral factor (THF), asparaginase, arginase, arginine deaminase, adenosine deaminase, superoxide dismutase, endotoxin enzyme, catalase, chymosin, lipase, uricase, adenosine diphosphatase, tyrosinase, bilirubin oxidase, glucose oxidase, glucosidase, galactosidase, glucocerebrosidase and glucuronidase.
[0018] The target protein can be encoded by amino acids selected from the group consisting of SEQ ID NO:9 to SEQ ID NO:19.
[0019] The present invention also relates to a nucleic acid comprising a nucleotide sequence encoding the above fusion protein.
[0020] The present invention also relates to an expression vector comprising the above nucleic acid.
[0021] The present invention also relates to cells transformed by the above expression vector.
[0022] The above-mentioned cells can be Escherichia coli, Bacillus subtilis, Bacillus thuringiensis, Salmonella typhimurium, Serratia marcescens, Pseudomonas, yeast, insect cells, Chinese hamster ovary cell line (CHO), W138, BHK, COS-7, 293, HepG2, 3T3, RIN, MDCK cell line or plant cells.
[0023] The present invention also relates to a method for expressing and purifying a target protein using a calpain tag, which comprises: step A), preparing an expression vector comprising a nucleic acid, wherein the nucleic acid encodes a fusion protein; step B), transducing the expression vector into a host cell to obtain a transformant; step C), expressing a fusion protein comprising a calpain tag and a target protein from the transformant; step D), precipitating the fusion protein comprising a calpain tag and a target protein from the expressed transformant using calcium; and step E), separating the target protein from the fusion protein using a hydrolase.
[0024] Effects of the Invention
[0025] According to the method for expressing, solubilizing and purifying a target protein using a calretinin tag of the present invention, due to the high expression and high water solubility of calretinin, poorly expressed or well-aggregated proteins can be expressed in an aqueous solution state, and can be easily separated and purified without a column by calcium precipitation, thereby hopefully reducing the cost of protein materials and drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 A schematic diagram showing the recombinant expression vector of the present invention.
[0027] Figure 2 A schematic diagram showing the method for expressing and purifying the target protein of the present invention.
[0028] Figure 3 The results of cloning the EDB target protein gene in CSQ1TEV or CSQ1Thrombin vector according to Example 1 are shown.
[0029] Figure 4The figure shows the results of purification of CSQ1TEV-EDB and CSQ1Thrombin-EDB proteins in Example 1, and the results of purification of EDB using a histidine tag and a glutathione S-transferase fusion protein, which are existing commercial tags. In the case of EDB14 protein, although it can be expressed using a histidine tag or a glutathione S-transferase tag, the target protein is not in the supernatant, and most of it aggregates into a precipitate (pellet) and is insoluble. However, in the case of EDB14, EDB21, and EDB26 proteins using a calretinin tag, although part of it aggregates into a precipitate, about 30% to 50% or more of the water-soluble protein is present in the supernatant (S), and it is confirmed that the target protein can be eluted.
[0030] Figure 5 The results of cleavage of calretinin 1 tobacco etch virus-EDB protein by tobacco etch virus protease (TEV protease) according to Example 1 are shown. After confirming that the calretin tag and EDB protein were separated by tobacco etch virus protease, calcium treatment was performed to precipitate and remove the separated calretin tag, thereby facilitating separation of the target protein EDB.
[0031] Figure 6 The results of cloning the epidermal growth factor target protein gene in the calretinin 1 tobacco etch virus and calretinin 1 thrombin vectors according to Example 2 are shown.
[0032] Figure 7 The results of purifying CSQ1Thrombin-EGF and CSQ1TEV-EGF proteins according to Example 2 are shown. It is known that the epidermal growth factor itself, which is originally expressed in bacteria, aggregates and 100% is present in the precipitate, but when the calretinin tag is used, 30% to 40% can be solubilized in water.
[0033] Figure 8 The results of cleavage of calpain 1 thrombin-epidermal growth factor protein by thrombin protease according to Example 2 are shown.
[0034] Fig. 9 The results of purifying the CSQ1TEV-KGF1 protein according to Example 3 are shown.
[0035] Fig.10The results of cleavage of calcein 1 tobacco etch virus-keratinocyte growth factor 1 protein using tobacco etch virus protease according to Example 3 are shown.
[0036] Fig.11 The results of purifying the CSQ1TEV-VEGF protein according to Example 3 are shown.
[0037] Fig.12 The results of cleavage of calcein 1 tobacco etch virus-vascular endothelial growth factor protein using tobacco etch virus protease according to Example 3 are shown.
[0038] Fig.13 The results of purifying the CSQ1TEV-FGF2 protein according to Example 3 are shown.
[0039] Fig.14 The results of cleavage of calcein 1 tobacco etch virus-fibroblast growth factor 2 protein using tobacco etch virus protease according to Example 3 are shown.
[0040] Fig.15 The results of cloning bone morphogenetic protein 2 (BMP2) and transforming growth factor β (TGFβ) target protein genes in tobacco etch virus calsequestrin 1 (TEVCSQ1) or thrombin calsequestrin 1 (ThrombinCSQ1) vectors according to Example 4 are shown.
[0041] Fig.16 The results of purifying the bone morphogenetic protein 2-tobacco etch virus calsequestrin 1 (BMP2-TEVCSQ1) and bone morphogenetic protein 2-thrombin calsequestrin 1 (BMP2-ThrombinCSQ1) proteins according to Example 4 are shown.
[0042] Fig.17 The results of cleavage of bone morphogenetic protein 2-tobacco etch virus calsequestrin 1 or bone morphogenetic protein 2-thrombin calsequestrin 1 protein using tobacco etch virus protease or thrombin protease according to Example 4 are shown.
[0043] Fig.18 The results of purification of transforming growth factor β-tobacco etch virus calsequestrin 1 (TGFβ-TEVCSQ1) and transforming growth factor β-thrombin calsequestrin 1 (TGFβ-ThrombinCSQ1) proteins according to Example 4 are shown.
[0044] Fig.19The results of cleavage of transforming growth factor β-tobacco etch virus calsegregant 1 or transforming growth factor β-thrombin calsegregant 1 protein using tobacco etch virus protease or thrombin protease according to Example 4 are shown.
[0045] Fig. 20 The results of purifying the horseradish peroxidase-tobacco etch virus sarcoma calsequestrin 1 (HRP-TEVCSQ1) protein according to Example 4 are shown.
[0046] Fig.21 The results of cleavage of horseradish peroxidase-tobacco etch virus calcein 1 protein using tobacco etch virus protease according to Example 4 are shown.
[0047] Fig. 22 The results of purifying the glucagon-like peptide 1-tobacco etch virus calsequestrin 1 GLP1-TEVCSQ1 protein according to Example 4 are shown.
[0048] Fig.23 The results of cleavage of the glucagon-like peptide 1-tobacco etch virus calcein 1 protein using tobacco etch virus protease according to Example 4 are shown.
[0049] Fig.24 The results of cloning bone morphogenetic protein 2 and keratinocyte growth factor 1 target protein genes in CSQ2TEV or CSQ2Thrombin vectors according to Example 5 are shown.
[0050] Fig.25 The results of purifying CSQ2TEV-BMP2 and CSQ2Thrombin-BMP2 proteins according to Example 5 are shown.
[0051] Fig.26 The results of cleavage of calcein 2 tobacco etch virus-bone morphogenetic protein 2 or calcein 2 thrombin-bone morphogenetic protein 2 protein using tobacco etch virus protease or thrombin protease according to Example 5 are shown.
[0052] Fig. 27 The results of purifying CSQ2TEV-KGF1 and CSQ2Thrombin-KGF1 proteins according to Example 5 are shown.
[0053] Fig.28The results of cleavage of calcein 2, tobacco etch virus-keratinocyte growth factor 1 or calcein 2, thrombin-keratinocyte growth factor 1 protein using tobacco etch virus protease or thrombin protease according to Example 5 are shown.
[0054] Fig.29 The results of purifying horseradish peroxidase-tobacco etch virus calsequestrin 2 (HRP-TEVCSQ2) and horseradish peroxidase-thrombin calsequestrin 2 (HRP-ThrombinCSQ2) proteins according to Example 6 are shown.
[0055] Fig.30 The results of cleavage of horseradish peroxidase-tobacco etch virus calcein 2 protein using tobacco etch virus protease according to Example 6 are shown.
[0056] Fig.31 The results of purifying the glucagon-like peptide 1-tobacco etch virus calsequestrin 2 (GLP1-TEVCSQ2) protein according to Example 6 are shown.
[0057] Fig.32 The results of cleavage of the glucagon-like peptide 1-tobacco etch virus calcein 2 protein using tobacco etch virus protease according to Example 6 are shown.
[0058] Fig.33 The results of purifying the CSQ1-Ssp Dna-epidermal growth factor (CSQ1-Ssp Dna-EGF) protein according to Example 7 are shown.
[0059] Fig.34 The results of cleavage of calretinin 1-Ssp Dna-epidermal growth factor protein using dithiothreitol (DTT) according to Example 7 are shown.
[0060] Fig.35 The results of purifying the CSQ2-SspDna-KGF1 protein according to Example 7 are shown.
[0061] Fig.36 The results of cleavage of calretinin 2-Ssp Dna-keratinocyte growth factor 1 protein using dithiothreitol according to Example 7 are shown.
[0062] Fig.37 The results of purifying the epidermal growth factor-GyrA-calretinin 1 protein according to Example 8 are shown.
[0063] Fig.38The results of cleavage of the epidermal growth factor-GyrA-calsequestrin 1 (EGF-GyrA-CSQ1) protein using 20 mM Na-HEPES (pH 6.5) buffer according to Example 8 are shown.
[0064] Fig.39 The results of purifying the bone morphogenetic protein 2-GyrA-Calsequestrin 2 (BMP2-GyrA-CSQ2) protein according to Example 8 are shown.
[0065] Fig.40 The results of cleavage according to Example 8 using 20 mM Na-HEPES (pH 6.5) buffer are shown. DETAILED DESCRIPTION
[0066] The term "calsequestrin (CSQ)" used in this specification is a calcium-binding protein of the sarcoplasmic reticulum, which can bind to calcium after muscle contraction to store calcium ions in the sarcoplasmic reticulum pool even if the calcium concentration in the sarcoplasmic reticulum is higher than that in the cytoplasm. One calsequestrin molecule can bind to multiple calcium (for example, each calsequestrin molecule has 40 to 50 calcium binding sites), and therefore has excellent calcium storage capacity. Calsequestrin has the following properties, that is, when the calcium content is low, it exists as a monomer, and when the calcium content increases, it becomes a polymer to increase its size.
[0067] The term "target protein" used in this specification refers to any protein that needs to be obtained in high purity or in large quantities for a specific purpose, including natural proteins, variant proteins, or novel recombinant proteins, etc. without limitation. The target protein can be a protein that needs to be obtained in high purity or in large quantities for industrial, medical, academic, etc. reasons, preferably a recombinant protein for medicine or research, more preferably, selected from the group consisting of high molecular weight proteins, glycoproteins, cytokines, growth factors, blood products, vaccines, hormones, enzymes, and antibodies. More preferably, the target protein can be all or part of the light chain or heavy chain of an antibody, most preferably the light chain variable region (VL) or heavy chain variable region (VH) of an antibody.
[0068] The term "peptide decomposed by a hydrolase" used in the present specification may be included between the calretinin tag and the target protein, and may be cleaved by a hydrolase to separate the calretinin tag and the target protein.
[0069] The term "vector" used in this specification is an expression vector that can express the target protein in an appropriate host cell, and refers to a nucleic acid construct that contains a necessary regulatory element that can be operably connected to express a nucleic acid insert. The above-mentioned vector includes plasmids, bacterial plasmids, phages, yeast plasmids, plant cell viruses, mammalian cell viruses or other vectors commonly used in the art, and can be prepared by operating plasmids commonly used in the art (for example, pSC101, pGV1106, pACYC177, ColE1, pKT230, pME290, pBR322, pUC8 / 9, pUC6, pBD9, pHC79, pIJ61, pLAFR1, pHV14, pGEX series, pET series and pUC19, etc.), phages (for example, λgt4λB, λ-Charon, λΔz1 and M13, etc.) or viruses (for example, CMV, SV40, etc.).
[0070] The term "transformation" used in this specification refers to the phenomenon of introducing deoxyribonucleic acid (DNA) into a host to replicate the deoxyribonucleic acid as a chromosomal factor or through chromosomal integration, and introducing external deoxyribonucleic acid into cells to artificially cause genetic changes. The above-mentioned transformation methods include CaCl2 precipitation method, Hanahan method using a reducing substance called dimethyl sulfoxide (DMSO) in the CaCl2 method to improve efficiency, electroporation, calcium phosphate precipitation method, protoplast fusion method, stirring method using silicon carbide fiber, Agrobacterium-mediated transformation method, transformation method using PEG, dextran sulfate, liposome and drying / inhibition-mediated transformation method, but are not limited to these.
[0071] The term "host cell" used in this specification refers to a cell that parasitizes other microorganisms or genes to provide nutrition, and refers to a cell in which a vector is transformed into a host cell to exert various gene or molecular effects in the host cell. The host cell that can stably and continuously clone and express the vector of the present invention in a prokaryotic cell can use any host cell known in the art, for example, Bacillus strains such as E. coli Rosetta, E. coli JM109, E. coli BL21, E. coli RR1, E. coli LE392, E. coli B, E. coli X 1776, E. coli W3110, Bacillus subtilis, Bacillus thuringiensis, and Enterobacteriaceae strains such as Salmonella typhimurium, Serratia marcescens, and various Pseudomonas. Furthermore, when the vector of the present invention is transformed into eukaryotic cells, yeast (Saccharomyce cerevisiae), insect cells, human cells (for example, Chinese hamster ovary cell lines, W138, BHK, COS-7, 293, HepG2, 3T3, RIN and MDCK cell lines) and plant cells can be used as host cells.
[0072] According to a first embodiment, the present invention provides a fusion protein comprising a calretinin tag and a target protein.
[0073] The present invention is characterized in that, in the fusion protein of the present invention, the calretinin tag comprises calretinin 1 (CSQ1) or calretinin 2 (CSQ2).
[0074] The present invention is characterized in that, in the fusion protein of the present invention, the above-mentioned calretinin 1 and calretinin 2 are encoded by amino acids consisting of SEQ ID NO: 1 and SEQ ID NO: 2, respectively. The amino acids of the above-mentioned SEQ ID NO: 1 can be encoded by the nucleotide sequence of SEQ ID NO: 3, and the amino acids of the above-mentioned SEQ ID NO: 2 can be encoded by the nucleotide sequence of SEQ ID NO: 4.
[0075] The present invention is characterized in that, in the fusion protein of the present invention, the calretinin tag and the target protein are fused via a hydrolase-degradable peptide composed of amino acids, and the amino acids are selected from the group consisting of SEQ ID NO: 5 to SEQ ID NO: 8.
[0076] The present invention is characterized in that, in the fusion protein of the present invention, the target protein is selected from the group consisting of high molecular weight proteins, glycoproteins, cytokines, growth factors, blood products, vaccines, hormones, enzymes and antibodies. For example, the target protein can be selected from interleukin 2, blood factor VII, blood factor VIII, blood factor IX, immunoglobulin, horseradish peroxidase, cytokines, α-interferon, β-interferon, γ-interferon, colony stimulating factor, human fibronectin extra domain B, bone morphogenetic protein, fibroblast growth factor, vascular endothelial growth factor, nerve growth factor, epidermal growth factor, insulin growth factor, transforming growth factor-α and transforming growth factor-β, brain-derived neurotrophic factor, platelet-derived growth factor, placental growth factor, hepatocyte growth factor, fibroblast growth factor-1 and fibroblast growth factor-2, keratinocyte growth factor, glucagon-like peptide-1, exendin, somatostatin, luteinizing hormone releasing hormone, adrenocorticotropic hormone, growth hormone releasing hormone, etc. The group consisting of hormones, oxytocin, thymosin alpha-1, corticotropin-releasing factor, calcitonin, bivalirudin, vasopressin, phospholipase activating protein, insulin, tumor necrosis factor, follicle-stimulating hormone, thyroid-stimulating hormone, antidiuretic hormone, pigment hormone, parathyroid hormone, luteinizing hormone, calcitonin gene-related peptide, enkephalin, somatomedin, erythropoietin, hypothalamic secretory factor, prolactin, chronic gonadotropin, tissue plasminogen activator, growth hormone-releasing peptide, thymic humoral factor, asparaginase, arginase, arginine deaminase, adenosine deaminase, superoxide dismutase, endotoxin enzyme, catalase, chymotrypsin, lipase, uricase, adenosine diphosphatase, tyrosinase, bilirubin oxidase, glucose oxidase, glucosidase, galactosidase, glucocerebrosidase and glucuronidase.
[0077] The present invention is characterized in that, in the fusion protein of the present invention, the target protein is encoded by amino acids selected from the group consisting of SEQ ID NO: 9 to SEQ ID NO: 19.
[0078] According to a second embodiment, the present invention provides a nucleic acid comprising a nucleotide sequence encoding a fusion protein and an expression vector comprising the nucleic acid, wherein the fusion protein comprises a calpain tag and a target protein.
[0079] The present invention is characterized in that, in the nucleic acid or expression vector of the present invention, the calretinin tag is encoded by an amino acid consisting of SEQ ID NO: 1 or SEQ ID NO: 2. The amino acid of SEQ ID NO: 1 can be encoded by a nucleotide sequence of SEQ ID NO: 3, and the amino acid of SEQ ID NO: 2 can be encoded by a nucleotide sequence of SEQ ID NO: 4.
[0080] The present invention is characterized in that, in the nucleic acid or expression vector of the present invention, the calretinin tag and the target protein can be decomposed into peptides by a hydrolase composed of amino acids, and the amino acids are selected from the group consisting of SEQ ID NO: 5 to SEQ ID NO: 8.
[0081] The present invention is characterized in that, in the nucleic acid or expression vector of the present invention, the target protein is selected from the group consisting of high molecular weight proteins, glycoproteins, cytokines, growth factors, blood products, vaccines, hormones, enzymes and antibodies. For example, the target protein can be selected from interleukin 2, blood factor VII, blood factor VIII, blood factor IX, immunoglobulin, horseradish peroxidase, cytokine, α-interferon, β-interferon, γ-interferon, colony stimulating factor, human fibronectin extra domain B, bone morphogenetic protein, fibroblast growth factor, vascular endothelial growth factor, nerve growth factor, epidermal growth factor, insulin growth factor, transforming growth factor-α and transforming growth factor-β, brain-derived neurotrophic factor, platelet-derived growth factor, placental growth factor, hepatocyte growth factor, fibroblast growth factor-1 and fibroblast growth factor-2, keratinocyte growth factor, glucagon-like peptide-1, exendin, somatostatin, luteinizing hormone releasing hormone, adrenocorticotropic hormone, growth hormone releasing hormone, leucocyte growth factor ... The group consisting of hormones, oxytocin, thymosin alpha-1, corticotropin-releasing factor, calcitonin, bivalirudin, vasopressin, phospholipase activating protein, insulin, tumor necrosis factor, follicle-stimulating hormone, thyroid-stimulating hormone, antidiuretic hormone, pigment hormone, parathyroid hormone, luteinizing hormone, calcitonin gene-related peptide, enkephalin, somatomedin, erythropoietin, hypothalamic secretory factor, prolactin, chronic gonadotropin, tissue plasminogen activator, growth hormone-releasing peptide, thymic humoral factor, asparaginase, arginase, arginine deaminase, adenosine deaminase, superoxide dismutase, endotoxin enzyme, catalase, chymotrypsin, lipase, uricase, adenosine diphosphatase, tyrosinase, bilirubin oxidase, glucose oxidase, glucosidase, galactosidase, glucocerebrosidase and glucuronidase.
[0082] The present invention is characterized in that, in the nucleic acid or expression vector of the present invention, the target protein is encoded by an amino acid selected from the group consisting of SEQ ID NO: 9 to SEQ ID NO: 19.
[0083] According to a third embodiment, the present invention provides a cell transformed with an expression vector comprising a fusion protein comprising a calretinin tag and a target protein.
[0084] The present invention is characterized in that, in the transformed cell of the present invention, the calretinin tag is encoded by an amino acid consisting of SEQ ID NO: 1 or SEQ ID NO: 2. The amino acid of SEQ ID NO: 1 can be encoded by a nucleotide sequence of SEQ ID NO: 3, and the amino acid of SEQ ID NO: 2 can be encoded by a nucleotide sequence of SEQ ID NO: 4.
[0085] The present invention is characterized in that, in the transformed cell of the present invention, the calretinin tag and the target protein can be fused to a peptide degradable by a hydrolase composed of amino acids, and the amino acids are selected from the group consisting of SEQ ID NO: 5 to SEQ ID NO: 8.
[0086] The present invention is characterized in that, in the transformed cells of the present invention, the target protein is selected from the group consisting of high molecular weight proteins, glycoproteins, cytokines, growth factors, blood products, vaccines, hormones, enzymes and antibodies. For example, the target protein can be selected from interleukin 2, blood factor VII, blood factor VIII, blood factor IX, immunoglobulin, horseradish peroxidase, cytokines, α-interferon, β-interferon, γ-interferon, colony stimulating factor, human fibronectin extra domain B, bone morphogenetic protein, fibroblast growth factor, vascular endothelial growth factor, nerve growth factor, epidermal growth factor, insulin growth factor, transforming growth factor-α and transforming growth factor-β, brain-derived neurotrophic factor, platelet-derived growth factor, placental growth factor, hepatocyte growth factor, fibroblast growth factor-1 and fibroblast growth factor-2, keratinocyte growth factor, glucagon-like peptide-1, exendin, somatostatin, luteinizing hormone-releasing hormone, adrenocorticotropic hormone, growth hormone releasing hormone, etc. The group consisting of hormones, oxytocin, thymosin alpha-1, corticotropin-releasing factor, calcitonin, bivalirudin, vasopressin, phospholipase activating protein, insulin, tumor necrosis factor, follicle-stimulating hormone, thyroid-stimulating hormone, antidiuretic hormone, pigment hormone, parathyroid hormone, luteinizing hormone, calcitonin gene-related peptide, enkephalin, somatomedin, erythropoietin, hypothalamic secretory factor, prolactin, chronic gonadotropin, tissue plasminogen activator, growth hormone-releasing peptide, thymic humoral factor, asparaginase, arginase, arginine deaminase, adenosine deaminase, superoxide dismutase, endotoxin enzyme, catalase, chymotrypsin, lipase, uricase, adenosine diphosphatase, tyrosinase, bilirubin oxidase, glucose oxidase, glucosidase, galactosidase, glucocerebrosidase and glucuronidase.
[0087] The present invention is characterized in that, in the transformed cell of the present invention, the target protein is encoded by an amino acid selected from the group consisting of SEQ ID NO: 9 to SEQ ID NO: 19.
[0088] The present invention is characterized in that, in the transformed cells of the present invention, the above-mentioned cells are Escherichia coli, Bacillus subtilis, Bacillus thuringiensis, Salmonella typhimurium, Serratia marcescens, Pseudomonas, yeast, insect cells, Chinese hamster ovary cell line, W138, BHK, COS-7, 293, HepG2, 3T3, RIN, MDCK cell line or plant cells.
[0089] According to a fourth example, the present invention provides a method for expressing and purifying a target protein using a calpain tag, the method comprising: step A), preparing an expression vector comprising a nucleic acid, wherein the nucleic acid encodes a fusion protein comprising a calpain tag and a target protein; step B), transducing the expression vector into a host cell to obtain a transformant; step C), expressing a fusion protein comprising a calpain tag and a target protein from the transformant; step D), precipitating the fusion protein comprising a calpain tag and a target protein from the expressed transformant using calcium; and step E), separating the target protein from the fusion protein using a hydrolase.
[0090] The present invention is characterized in that, in the target protein expression and purification method of the present invention, the calretinin tag is encoded by amino acids consisting of SEQ ID NO: 1 or SEQ ID NO: 2. The amino acids of SEQ ID NO: 1 can be encoded by the nucleotide sequence of SEQ ID NO: 3, and the amino acids of SEQ ID NO: 2 can be encoded by the nucleotide sequence of SEQ ID NO: 4.
[0091] The present invention is characterized in that, in the target protein expression and purification method of the present invention, the calretinin tag and the target protein can be fused by a hydrolase-degradable peptide composed of amino acids, and the amino acids are selected from the group consisting of SEQ ID NO: 5 to SEQ ID NO: 8.
[0092] The present invention is characterized in that, in the target protein expression and purification method of the present invention, the target protein can be selected from the group consisting of high molecular weight protein, glycoprotein, cytokine, growth factor, blood preparation, vaccine, hormone, enzyme and antibody. For example, the target protein can be selected from interleukin 2, blood factor VII, blood factor VIII, blood factor IX, immunoglobulin, horseradish peroxidase, cytokine, α-interferon, β-interferon, γ-interferon, colony stimulating factor, human fibronectin extra domain B, bone morphogenetic protein, fibroblast growth factor, vascular endothelial growth factor, nerve growth factor, epidermal growth factor, insulin growth factor, transforming growth factor-α and transforming growth factor-β, brain-derived neurotrophic factor, platelet-derived growth factor, placental growth factor, hepatocyte growth factor, fibroblast growth factor-1 and fibroblast growth factor-2, keratinocyte growth factor, glucagon-like peptide-1, exendin, somatostatin, luteinizing hormone releasing hormone, adrenocorticotropic hormone, growth hormone releasing hormone The group consisting of hormones, oxytocin, thymosin alpha-1, corticotropin-releasing factor, calcitonin, bivalirudin, vasopressin, phospholipase activating protein, insulin, tumor necrosis factor, follicle-stimulating hormone, thyroid-stimulating hormone, antidiuretic hormone, pigment hormone, parathyroid hormone, luteinizing hormone, calcitonin gene-related peptide, enkephalin, somatomedin, erythropoietin, hypothalamic secretory factor, prolactin, chronic gonadotropin, tissue plasminogen activator, growth hormone-releasing peptide, thymic humoral factor, asparaginase, arginase, arginine deaminase, adenosine deaminase, superoxide dismutase, endotoxin enzyme, catalase, chymotrypsin, lipase, uricase, adenosine diphosphatase, tyrosinase, bilirubin oxidase, glucose oxidase, glucosidase, galactosidase, glucocerebrosidase and glucuronidase.
[0093] The present invention is characterized in that, in the method for expressing and purifying a target protein of the present invention, the target protein is encoded by an amino acid selected from the group consisting of SEQ ID NO: 9 to SEQ ID NO: 19.
[0094] Embodiments of the present invention
[0095] In order to help understand the invention, various embodiments are presented below. The following embodiments are provided only to make the invention easier to understand, and the protection scope of the invention is not limited to the following embodiments.
[0096] Example
[0097] Example 1: Isolation of EDB using calretinin tag
[0098] 1-1. Cloning EDB in calcein-1 tobacco etch virus or calcein-1 thrombin vector (Vector)
[0099] To clone EDB in the calreceptin 1 tobacco etch virus or calreceptin 1 thrombin vector, the following oligonucleotides EDB-F1 and EDB-B1 were synthesized (Bioneer, Daejeon, Korea). In addition, as a comparative example, a fusion protein of a known histidine tag or glutathione S-transferase tag and EDB was prepared.
[0100] 5'-AATGGATCCGAGGTGCCCCAACTCACTGAC-3'(SEQ ID NO:20)
[0101] 5'-ATTTCCGAGTTACGTTTGTTGTGTCAGTGTAGTAGG-3'(SEQ ID NO:21)
[0102] For amplification, 20 pmol of EDB-F1, 20 pmol of EDB-B1, 4 μl of PCR PreMix (Elpisbio, Daejeon, Korea) and 10 μg of template were mixed to prepare a mixture of 20 μl of distilled water. The mixture was subjected to polymerase chain reaction (5 minutes at 95°C, 30 times: 30 seconds at 95°C, 30 seconds at 42°C, 45 seconds at 72°C and 5 minutes at 72°C) for amplification, and then purified (PCR purification kit, GeneAll, Seoul, Korea) to obtain EDB14 (SEQ ID NO: 9), EDB21 (SEQ ID NO: 10), and EDB26 (SEQ ID NO: 11) genes. To insert the EDB gene into the calreceptin 1 tobacco etch virus or calreceptin 1 thrombin vector, the calreceptin 1 tobacco etch virus or calreceptin 1 thrombin vector and the insert DNA are treated with restriction enzymes. About 1 μg of the inserted DNA was reacted with BamHI (New England Biolabs (NEB, Ipswich)) and XhoI (NEB, Ipswich) for one day, and then purified using a polymerase chain reaction purification kit. In addition, calf intestinal alkaline phosphatase (CIAP) (NEB, Ipswich) was added to about 40 μg of calreticulin 1 tobacco etch virus or calreticulin 1 thrombin vector and reacted for 3 hours, and then purified using a polymerase chain reaction purification kit. The inserted DNA was ligated with the calreticulin tobacco etch virus or calreticulin 1 thrombin vector at room temperature for 3 hours (Bioneer, Daejeon, South Korea). Figure 3 ).
[0103] After that, transform the DNA of the calreticulin 1 tobacco etch virus or calreticulin 1 thrombin vector and the EDB insert ligation reaction. Thaw the competent cells DH5a on ice, mix with 2μl of the solution of the competent cell ligation reaction in 100μl, and react for 30 minutes. In addition, heat shock at 42°C for 1 minute, add 200μl to the SOC medium, culture at 37°C for 30 minutes and apply. Randomly take 6 colonies from the coated colonies for polymerase chain reaction, and electrophoresed the DNA to confirm the insert. Entrust Bioneer to sequence to confirm the cloned colonies.
[0104] As a comparative example, a fusion protein of a histidine tag or a glutathione S transferase tag and EDB was cloned in pBT7-N-histidine (pBT7-N-His) and pBT7-N-glutathione S transferase vectors provided by Bioneer by the method described above.
[0105] 1-2. Purification of calpain 1 tobacco etch virus-EDB, calpain 1 thrombin-EDB, histidine-EDB (His-EDB), glutathione S-transferase-EDB
[0106] After all the DNA sequences confirmed in Bioneer were converted to BL21 cells, they were spread on agar medium containing ampicillin. After the colonies grown in the agar plate medium were inoculated into 5 ml of LB medium containing ampicillin (50 μg / ml), they were mixed and cultured at 200 rpm for one day at a temperature of 37°C, and then mixed with glycerol at a ratio of 1:1 to prepare 1 ml of stock and stored in a deep freezer at -80°C. 100 μl of the raw material was inoculated into 20 ml of LB medium containing ampicillin (50 μg / ml), mixed and cultured at 200 rpm for one day at a temperature of 37°C, and then transferred into 400 ml of LB medium containing ampicillin (50 μg / ml) and cultured to OD=0.7. Afterwards, 1 mM of isopropyl-β-d-thiogalactoside (IPTG) was added and cultured at 200 rpm for one day at a temperature of 18°C. Centrifuge at 4000 rpm for 20 minutes at 4°C, remove all supernatants except precipitated cells, and suspend with lysis buffer (20 mM Tris (pH 8.0), 300 mM NaCl, and 10 mM imidazole). After storing at -80°C for one day, take out and completely dissolve, dissolve 10 mg of phenylmethanesulfonyl fluoride (PMSF) in 1 ml of dimethyl sulfoxide, and add 1 ml to the dissolved Escherichia coli (E. coli). After dissolving the E. coli using a sonicator, centrifuge at 13000 rpm for 1 hour at 4°C. Add 20 mM CaCl2 to the supernatant and react at 4°C for 1 hour. After that, centrifuge at 5000 rpm for 30 minutes. The supernatant was removed, and ethylenediaminetetraacetic acid (EDTA) was added to the precipitate and suspended to obtain calretinin 1 tobacco etch virus-EDB and calretinin 1 thrombin-EDB proteins ( Figure 4 ).
[0107] Histidine-EDB was expressed and purified by the following method. After the conversion of EDB14 cloned in the pBT7-N-histidine vector to BL21 cells, it was coated on an agar medium containing ampicillin. After the colonies grown in the agar plate medium were inoculated in 5ml of LB medium containing ampicillin (50μg / ml), they were mixed and cultured at a speed of 220rpm at a temperature of 37°C for one day, and then mixed with glycerol at a ratio of 1:1 to prepare 1ml of raw materials and stored in a quick freezer at -80°C. 100μl of raw materials were inoculated in 20ml of LB medium containing ampicillin (50μg / ml), mixed and cultured at a speed of 220rpm at a temperature of 37°C for one day, and then moved into 400ml of LB medium containing ampicillin (50μg / ml) and cultured to OD=0.7. Afterwards, 1mM of isopropyl-β-d-thiogalactoside was added and cultured at a temperature of 37°C at a speed of 220rpm for one day. The cells were centrifuged at 4000 x g for 10 minutes at 4°C, all supernatants except the precipitated cells were removed, and the cells were suspended in a lysis buffer (50 mM sodium phosphate (pH 8.0), 300 mM NaCl, and 10 mM imidazole). After being stored at -80°C for one day, the cells were taken out and completely dissolved, 10 mg of phenylmethanesulfonyl fluoride was dissolved in 1 ml of isopropanol, and 1 ml was added to the dissolved E. coli.
[0108] After dissolving E. coli using a sonicator, centrifugation was performed at 13,000 rpm for 1 hour at 4°C. After washing Ni-NTA affinity resin (Elposbio, Daejeon, South Korea) with distilled water and lysis buffer, the supernatant was bound to the resin. After washing with 600 ml of washing buffer (50 mM sodium phosphate (pH 8.0), 300 mM NaCl, and 20 mM imidazole), the N-terminal histidine-tagged EDB14 protein ( Figure 4 ).
[0109] Glutathione S transferase-EDB was expressed and purified by the following method. After the conversion of EDB14 cloned in the pBT7-N-glutathione S transferase vector to BL21 cells, it was coated on an agar medium containing ampicillin. After the colonies grown in the agar plate medium were inoculated in 5ml of LB medium containing ampicillin (50μg / ml), they were mixed and cultured at a speed of 220rpm at a temperature of 37°C for one day, and then mixed with glycerol at a ratio of 1:1 to prepare 1ml of raw materials and stored in a quick freezer at -80°C. 100μl of raw materials were inoculated in 20ml of LB medium containing ampicillin (50μg / ml), mixed and cultured at a speed of 220rpm at a temperature of 37°C for one day, and then moved into 400ml of LB medium containing ampicillin (50μg / ml) and cultured to OD=0.7. After that, 1mM isopropyl-β-d-thiogalactoside was added and cultured at 37°C at 220rpm for one day. Centrifuge at 4000xg for 10 minutes at 4°C to remove all supernatants except the precipitated cells and use lysis buffer (50mM Tris (pH 7.5), 150mM NaCl and 0.05% NP-40). After being stored at -80°C for one day, the cells were taken out and completely dissolved, 10mg of phenylmethanesulfonyl fluoride was dissolved in 1ml of isopropanol, and 1ml was added to the dissolved Escherichia coli.
[0110] After dissolving Escherichia coli using a sonicator, centrifuge at 13,000 rpm for 1 hour at 4°C. After washing glutathione S-transferase-bound agarose resin (GST.Bind Agarose Resin) (Elposbio, Daejeon, South Korea) with distilled water and lysis buffer, the supernatant was bound to the resin. After washing with 600 ml of washing buffer (50 mM Tris-Cl (pH 8.0), 150 mM NaCl and 0.1 mM ethylenediaminetetraacetic acid), the N-terminal glutathione S-transferase-tagged EDB14 protein ( Figure 4 ).
[0111] As a result, it was confirmed that the EDB14 protein could not be expressed in the supernatant using a histidine tag or a glutathione S-transferase tag, but could be solubilized in water and expressed in the supernatant using a calretinin tag.
[0112] 1-3. Isolation of EDB using tobacco etch virus protease
[0113] In order to separate only EDB from calsequestrin 1 tobacco etch virus-EDB protein, 5 μl of tobacco etch virus protease (Genscript, USA) was added and reacted at 30°C for one day, and then sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was used to confirm ( Figure 5 The results confirmed that the calpain tag and EDB fusion protein can be easily separated by tobacco etch virus protease after calcium precipitation.
[0114] Example 2: Isolation of epidermal growth factor using calpain tag
[0115] 2-1. Cloning of epidermal growth factor in calpain-1 tobacco etch virus and calpain-1 thrombin vector
[0116] To clone EGF in the calcein-1 tobacco etch virus and calcein-1 thrombin vectors, the following two oligonucleotides, EGF-F1 and EGF-B1 (Bioneer, Daejeon, Korea), were synthesized.
[0117] 5'-AATGGATCCAACTCTGATAGCGAATGCCCG-3'(SEQ ID NO:22)
[0118] 5'-ATTCTCGAGTTA ACGCAGTTCCCACCATTT-3'(SEQ ID NO:23)
[0119] For amplification, 20 pmol of epidermal growth factor-F1 (EGF-F1), 20 pmol of epidermal growth factor-B1 (EGF-B1), 4 μl of polymerase chain reaction premix (Elpisbio, Daejeon, South Korea) and 10 μg of template were mixed to prepare a mixture of 20 μl of distilled water. The mixture was subjected to polymerase chain reaction (5 minutes at 95°C, 30 times: 30 seconds at 95°C, 30 seconds at 42°C, 45 seconds at 72°C and 5 minutes at 72°C) for amplification, and then the epidermal growth factor gene (SEQ ID NO: 12) was obtained by purification (polymerase chain reaction purification kit, GeneAll, Seoul, South Korea). In order to insert the epidermal growth factor gene into the calretinin 1 tobacco etch virus and calretinin 1 thrombin vector, the vector and the insert DNA were treated with restriction enzymes. About 1 μg of the inserted DNA was reacted with BamHI (New England Biolabs (NEB, Ipswich) and XhoI (NEB, Ipswich) for one day, and then purified using a polymerase chain reaction purification kit. In addition, calf intestinal alkaline phosphatase (NEB, Ipswich) was added to about 40 μg of calreticulin 1 tobacco etch virus and calreticulin 1 thrombin vector and reacted for 3 hours, and then purified using a polymerase chain reaction purification kit. The inserted DNA was ligated to the vector using T4 DNA ligase (Bioneer, Daejeon, South Korea) at room temperature for 3 hours ( Figure 6 ).
[0120] After that, transform the DNA of the ligation reaction of the calretinin 1 tobacco etch virus or calretinin 1 thrombin vector with the epidermal growth factor insert. Thaw the competent cells DH5a on ice, mix with 2μl of the solution of the competent cell ligation reaction in 100μl, and react for 30 minutes. In addition, heat shock at 42°C for 1 minute, add 200μl to the SOC medium, culture at 37°C for 30 minutes and spread. Randomly take 6 colonies from the spread for polymerase chain reaction, and electrophoresed the DNA to confirm the insert. Bioneer was commissioned to sequence to confirm the cloned colonies.
[0121] 2-2. Purification of calpain 1, thrombin-epidermal growth factor or calpain 1, tobacco etch virus-epidermal growth factor
[0122] After the DNA sequence confirmed in Bioneer was converted to BL21 cells, it was spread on an agar medium containing ampicillin. After the colonies grown in the agar plate medium were inoculated into 5 ml of LB medium containing ampicillin (50 μg / ml), they were mixed and cultured at 200 rpm for one day at a temperature of 37°C, and then mixed with glycerol at a ratio of 1:1 to prepare 1 ml of raw materials and stored in a quick freezer at -80°C. 100 μl of raw materials were inoculated into 20 ml of LB medium containing ampicillin (50 μg / ml), mixed and cultured at 200 rpm for one day at a temperature of 37°C, and then moved into 400 ml of LB medium containing ampicillin (50 μg / ml) and cultured to OD = 0.7. Afterwards, 1 mM of isopropyl-β-d-thiogalactoside was added and cultured at 200 rpm for one day at a temperature of 18°C. Centrifuge at 4000 rpm for 20 minutes at 4°C, remove all supernatant except precipitated cells, and suspend with lysis buffer (20 mM Tris (pH 8.0), 300 mM NaCl and 10 mM imidazole). After storing at -80°C for one day, take out and completely dissolve, dissolve 10 mg of phenylmethanesulfonyl fluoride in 1 ml of dimethyl sulfoxide, and add 1 ml to the dissolved Escherichia coli. After dissolving the Escherichia coli with a sonicator, centrifuge at 13000 rpm for 1 hour at 4°C. Add 20 mM CaCl2 to the supernatant and react at 4°C for 1 hour. Thereafter, centrifuge at 5000 rpm for 30 minutes. Remove the supernatant, add ethylenediaminetetraacetic acid to the precipitate and suspend it to obtain calpain 1, thrombin-epidermal growth factor and calpain 1, tobacco etch virus-epidermal growth factor protein ( Figure 7 ).
[0123] 2-3. Separation of epidermal growth factor using thrombin protease
[0124] In order to separate only EGF from calsequestrin 1 thrombin-EGF protein, 5 μl of thrombin protease was added and reacted at 22°C for one day, and then confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis ( Figure 8 ). The results confirmed that the calpain tag and EGF fusion protein can be easily separated using thrombin protease.
[0125] Example 3: Separation of keratinocyte growth factor 1, vascular endothelial growth factor and its components using calpain labeling Fibroblast Growth Factor 2
[0126] 3-1. Purification of calcein 1 tobacco etch virus-keratinocyte growth factor 1, calcein 1 tobacco etch virus-vascular endothelial growth factor and calcein 1 tobacco etch virus-fibroblast growth factor 2
[0127] After synthesizing the genes of keratinocyte growth factor 1 (SEQ ID NO: 13), vascular endothelial growth factor (SEQ ID NO: 14) and fibroblast growth factor 2 (SEQ ID NO: 15) at Bioneer, the calcein 1 tobacco etch virus clone was transformed into BL21 cells and then coated on an agar medium containing ampicillin. After the colonies grown in the agar plate medium were inoculated in 5 ml of LB medium containing ampicillin (50 μg / ml), they were mixed and cultured at 37°C at a speed of 200 rpm for one day, and then mixed with glycerol at a ratio of 1:1 to prepare 1 ml of raw materials and stored in a quick freezer at -80°C. 100 μl of raw materials were inoculated in 30 ml of LB medium containing ampicillin (50 μg / ml), mixed and cultured at a speed of 200 rpm for one day at 37°C, and then transferred into 1 L of LB medium containing ampicillin (50 μg / ml) and cultured to OD = 0.6. After that, add 1mM isopropyl-β-d-thiogalactoside and culture at 200rpm for one day at 17°C. Centrifuge at 4000rpm for 20 minutes at 4°C, remove all supernatants except the precipitated cells, and suspend with lysis buffer (20mM Tris (pH 8.0), 300mM NaCl and 10mM imidazole). After being stored at -80°C for one day, take out and completely dissolve, dissolve 10mg of phenylmethanesulfonyl fluoride in 1ml of dimethyl sulfoxide, and add 1ml to the dissolved Escherichia coli. After dissolving the Escherichia coli with a sonicator, centrifuge at 13000rpm for 1 hour at 4°C. Add 20mM CaCl2 to the supernatant and react at 4°C for 1 hour. After that, centrifuge at 5000rpm for 30 minutes. The supernatant was removed, and ethylenediaminetetraacetic acid was added to the precipitate and suspended to obtain calpain 1 tobacco etch virus-keratinocyte growth factor 1, calpain 1 tobacco etch virus-vascular endothelial growth factor and calpain 1 tobacco etch virus-fibroblast growth factor 2 proteins ( Fig. 9 , Fig.11 , Fig.13 ).
[0128] 3-2. Isolation of keratinocyte growth factor 1, vascular endothelial growth factor and fibroblast growth factor 2 using tobacco etch virus protease
[0129] In order to separate only keratinocyte growth factor 1 from calcein 1 tobacco etch virus-keratinocyte growth factor 1 protein (hereinafter, the same experiment as calcein 1 tobacco etch virus-vascular endothelial growth factor and calcein 1 tobacco etch virus-fibroblast growth factor proteins was performed), 5 μl of tobacco etch virus protease (Genscript, USA) was added and reacted at 30°C for one day, and then confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis ( Fig.10 , Fig.12 , Fig.14 The results confirmed that the calpain tag and keratinocyte growth factor 1 fusion protein, the calpain tag and epidermal growth factor V protein, and the calpain tag and fibroblast growth factor protein could be easily separated using tobacco etch virus protease.
[0130] Example 4: Separation of bone morphogenetic protein 2, transforming growth factor β, and horseradish peroxide using calretinin tag Glucagon-like peptide 1
[0131] 4-1. Cloning of BMP-2 and TGF-β in Tobacco Etch Virus Calretinin 1 or Thrombin Calretinin 1 Vector
[0132] To clone bone morphogenetic protein 2 and transforming growth factor β in tobacco etch virus calsegregant 1 or thrombin calsegregant 1 vectors, the following oligonucleotides Amplify-F1 and Amplify-B1 (Bioneer, Daejeon, Korea) were synthesized.
[0133] 5'-CAGCAAGACAGCGATGGATCC-3'(SEQ ID NO:24)
[0134] 5'-CGACTTACAGGTGATCTCGAG-3'(SEQ ID NO:25)
[0135] For amplification, 20 pmol of Amplify-F1, 20 pmol of Amplify-B1, polymerase chain reaction premix (Bioneer, Daejeon, South Korea) and 10 ug of template were mixed to prepare a mixture of 20 μl with distilled water added. The mixture was subjected to polymerase chain reaction (5 minutes at 95°C, 30 times: 30 seconds at 95°C, 30 seconds at 47°C, 45 seconds at 72°C and 5 minutes at 72°C) for amplification, and then the bone morphogenetic protein 2 (SEQ ID NO: 16) and transforming growth factor β (SEQ ID NO: 17) genes were obtained by purification (polymerase chain reaction purification kit, GeneAll, Seoul, South Korea). In order to insert the bone morphogenetic protein 2 gene (hereinafter, the same experiment as that of bone morphogenetic protein 2 is performed in the case of transforming growth factor β gene) into the tobacco etch virus calsequestrin 1 or thrombin calsequestrin 1 vector, the tobacco etch virus calsequestrin 1 or thrombin calsequestrin 1 vector and the insert DNA are treated with restriction enzymes. About 1 μg of the inserted DNA was reacted with BamHI (New England Biolabs (NEB, Ipswich) for one day and then with XhoI (NEB, Ipswich) for two days. After that, the purified DNA was obtained using a polymerase chain reaction purification kit. In addition, calf intestinal alkaline phosphatase (Takara, Japan) was added to about 3 μg of tobacco etch virus calretinin or thrombin calretinin vector and reacted for 3 hours, and then purified using a polymerase chain reaction purification kit. The inserted DNA was ligated to the tobacco etch virus calretinin or thrombin calretinin vector at room temperature for 3 hours (T4 DNA ligase (Bioneer, Daejeon, South Korea). Fig.15 ).
[0136] After that, the deoxyribonucleic acid of the tobacco etch virus muscle calcein 1 or thrombin muscle calcein 1 vector and the bone morphogenetic protein 2 insert was transformed. The competent cells DH5a were thawed on ice, mixed with 5μl of the solution of the competent cell connection reaction in 100μl, and reacted for 30 minutes. In addition, heat shock was performed at a temperature of 42°C for 30 seconds, and after adding 200μl to the SOC medium, it was cultured at a temperature of 37°C for 40 minutes and coated. The colonies obtained from the coating were randomly taken out, and Bioneer was commissioned to sequence to confirm the cloned colonies. After Bioneer also synthesized the horseradish peroxidase (SEQID NO: 18) and glucagon-like peptide 1 (SEQ ID NO: 19) genes, they were cloned in tobacco etch virus muscle calcein 1 by the method described above.
[0137] 4-2. Purified bone morphogenetic protein 2-tobacco etch virus calcein 1 or bone morphogenetic protein 2-thrombin calcein 1, transforming growth factor β-tobacco etch virus calcein 1 or transforming growth factor β-thrombin calcein 1, horseradish peroxidase-tobacco etch virus calcein 1 and glucagon-like peptide 1-tobacco etch virus calcein 1
[0138] Bone morphogenetic protein 2-tobacco etch virus calcein 1, bone morphogenetic protein 2-thrombin calcein 1, transforming growth factor β-tobacco etch virus calcein 1, transforming growth factor β-thrombin calcein 1, horseradish peroxidase-tobacco etch virus calcein 1, glucagon-like peptide-tobacco etch virus calcein 1 vectors with sequence confirmed in Bioneer were respectively transformed into BL21 cells and then coated on agar medium containing ampicillin. The colonies grown in the agar plate medium were inoculated into 5 ml of LB medium containing ampicillin (50 μg / ml), mixed and cultured at 37°C at a speed of 200 rpm for one day, and then mixed with glycerol at a ratio of 1:1 to prepare 1 ml of raw materials and stored in a quick freezer at -80°C. 100 μl of the raw material was inoculated into 30 ml of LB medium containing ampicillin (50 μg / ml), mixed and cultured at 200 rpm for one day at 37°C, and then transferred into 1 L of LB medium containing ampicillin (50 μg / ml) and cultured to OD = 0.6. After that, 1 mM of isopropyl-β-d-thiogalactoside was added and cultured at 200 rpm for one day at 17°C. Centrifuge at 4000 rpm for 20 minutes at 4°C, remove all supernatants except the precipitated cells, and suspend with lysis buffer (20 mM Tris (pH 8.0), 300 mM NaCl and 10 mM imidazole). After being stored at -80°C for one day, take out and completely dissolve, dissolve 10 mg of phenylmethanesulfonyl fluoride in 1 ml of dimethyl sulfoxide, and add 1 ml to the dissolved Escherichia coli. After dissolving E. coli using a sonicator, centrifuge at 13,000 rpm for 1 hour at 4°C. Add 20 mM CaCl2 to the supernatant and react at 4°C for 1 hour. Then, centrifuge at 5,000 rpm for 30 minutes. Remove the supernatant, add ethylenediaminetetraacetic acid to the precipitate and suspend it to obtain bone morphogenetic protein 2-tobacco etch virus muscle calretinin 1 and bone morphogenetic protein 2-thrombin muscle calretinin 1 protein ( Fig.16 , Fig.18 , Fig. 20 , Fig. 22 ).
[0139] 4-3. Separation of bone morphogenetic protein 2, transforming growth factor β, horseradish peroxidase and glucagon-like peptide 1 using tobacco etch virus protease
[0140] In order to separate bone morphogenetic protein 2 from bone morphogenetic protein 2-tobacco etch virus calcein 1 protein (hereinafter, the same experiment as bone morphogenetic protein 2-tobacco etch virus calcein 1 was also performed in the case of transforming growth factor β-tobacco etch virus calcein 1, horseradish peroxidase-tobacco etch virus calcein 1 and glucagon-like peptide 1-tobacco etch virus calcein 1 protein), 2 μl of tobacco etch virus protease (Genscript, USA) was added and reacted at 30°C for one day, and then confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis ( Fig.17 , Fig.19 , Fig.21 , Fig.23 The results confirmed that the calcein tag and bone morphogenetic protein 2 fusion protein can be easily separated using tobacco etch virus protease.
[0141] 4-4. Separation of Bone Morphogenetic Protein 2 and Transforming Growth Factor β Using Thrombin Protease
[0142] In order to separate bone morphogenetic protein 2 from bone morphogenetic protein 2-thrombin calcein 1 protein (hereinafter, the same experiment as bone morphogenetic protein 2-tobacco etch virus calcein 1 protein was also performed in the case of transforming growth factor β-tobacco etch virus calcein 1 protein), 5 μl of thrombin protease was added and reacted at 22°C for one day, and then confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis ( Fig.17 , Fig.19 ). The results confirmed that the calpain tag and bone morphogenetic protein 2 fusion protein can be easily separated using thrombin protease.
[0143] Example 5. Separation of bone morphogenetic protein 2 and keratinocyte growth factor 1 using calretinin-tag
[0144] 5-1. Cloning of bone morphogenetic protein 2 and keratinocyte growth factor 1 in calpain-2 tobacco etch virus or calpain-2 thrombin vector
[0145] To clone bone morphogenetic protein 2 and keratinocyte growth factor 1 in the calcein 2 tobacco etch virus or calcein 2 thrombin vector, the synthetic oligonucleotides Amplify-F1 and Amplify-B1 (Bioneer, Daejeon, South Korea) were used. For amplification, 20 pmol of Amplify-F1, 20 pmol of Amplify-B1, polymerase chain reaction premix (Bioneer, Daejeon, South Korea) and 10 ug of template were mixed to prepare a total of 20 μl of the mixture with distilled water added. The mixed solution was subjected to polymerase chain reaction (5 minutes at 95°C, 30 times: 30 seconds at 95°C, 30 seconds at 47°C, 45 seconds at 72°C, and 5 minutes at 72°C) for amplification, and then purified (PCR purification kit, GeneAll, Seoul, Korea) to obtain bone morphogenetic protein 2 (SEQ ID NO: 16) and keratinocyte growth factor 1 (SEQ ID NO: 13) genes. In order to insert the bone morphogenetic protein 2 gene (hereinafter, the same experiment as that of bone morphogenetic protein 2 was performed in the case of keratinocyte growth factor 1 gene) into the calretinin 2 tobacco etch virus or calretinin 2 thrombin vector, the calretinin 2 tobacco etch virus or calretinin 2 thrombin vector and the insert DNA were treated with restriction enzymes. About 1 μg of the inserted DNA was reacted with BamHI (New England Biolabs (NEB, Ipswich) for one day and then with XhoI (NEB, Ipswich) for two days. After that, the purified DNA was obtained using a polymerase chain reaction purification kit. In addition, calf intestinal alkaline phosphatase (Takara, Japan) was added to about 3 μg of calreticulin 2 tobacco etch virus or calreticulin 2 thrombin vector and reacted for 3 hours, and then purified using a polymerase chain reaction purification kit. The inserted DNA was ligated with the calreticulin 2 tobacco etch virus or calreticulin 2 thrombin vector at room temperature for 3 hours (T4 DNA ligase (Bioneer, Daejeon, South Korea)). Fig.24 ).
[0146] After that, transform the DNA of the ligation reaction of the calreticulin 2 tobacco etch virus or calreticulin 2 thrombin vector with the bone morphogenetic protein 2 insert. Thaw the competent cells DH5a on ice, mix with 5μl of the solution of the competent cell ligation reaction in 100μl, and react for 30 minutes. In addition, heat shock at 42°C for 30 seconds, add 200μl to the SOC medium, culture at 37°C for 40 minutes and apply. The colonies obtained from the application were randomly taken out and sequenced by Bioneer to confirm the cloned colonies.
[0147] 5-2. Purification of calretinin 2, tobacco etch virus-bone morphogenetic protein 2 or calretinin 2, thrombin-bone morphogenetic protein 2 and calretinin 2, tobacco etch virus-keratinocyte growth factor 1 or calretinin 2, thrombin-keratinocyte growth factor 1
[0148] After all the DNA sequences confirmed in Bioneer were converted to BL21 cells, they were spread on agar medium containing ampicillin. After the colonies grown in the agar plate medium were inoculated into 5 ml of LB medium containing ampicillin (50 μg / ml), they were mixed and cultured at 200 rpm for one day at a temperature of 37°C, and then mixed with glycerol at a ratio of 1:1 to prepare 1 ml of raw materials and stored in a quick freezer at -80°C. 100 μl of raw materials were inoculated into 30 ml of LB medium containing ampicillin (50 μg / ml), mixed and cultured at 200 rpm for one day at a temperature of 37°C, and then moved into 1 L of LB medium containing ampicillin (50 μg / ml) and cultured to OD = 0.6. Afterwards, 1 mM of isopropyl-β-d-thiogalactoside was added and cultured at 200 rpm for one day at a temperature of 17°C. Centrifuge at 4000 rpm for 20 minutes at 4°C, remove all supernatant except precipitated cells, and suspend with lysis buffer (20 mM Tris (pH 8.0), 300 mM NaCl and 10 mM imidazole). After storing at -80°C for one day, take out and completely dissolve, dissolve 10 mg of phenylmethanesulfonyl fluoride in 1 ml of dimethyl sulfoxide, and add 1 ml to the dissolved Escherichia coli. After dissolving the Escherichia coli with a sonicator, centrifuge at 13000 rpm for 1 hour at 4°C. Add 20 mM CaCl2 to the supernatant and react at 4°C for 1 hour. Thereafter, centrifuge at 5000 rpm for 30 minutes. Remove the supernatant, add ethylenediaminetetraacetic acid to the precipitate and suspend it to obtain calretinin 2 tobacco etch virus-bone morphogenetic protein 2 and calretinin 2 thrombin-bone morphogenetic protein 2 protein ( Fig.25 , Fig. 27 ).
[0149] 5-3. Isolation of bone morphogenetic protein 2 and keratinocyte growth factor using tobacco etch virus protease
[0150] In order to separate bone morphogenetic protein 2 from calcein 2 tobacco etch virus-bone morphogenetic protein 2 protein (hereinafter, the same experiment was performed in the case of calcein 2 tobacco etch virus-keratinocyte growth factor 1 protein), 2 μl of tobacco etch virus protease (Genscript, USA) was added and reacted at 30°C for one day, and then confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis ( Fig.26 , Fig.28 The results confirmed that the calcein tag and bone morphogenetic protein 2 fusion protein can be easily separated using tobacco etch virus protease.
[0151] 5-4. Separation of bone morphogenetic protein 2 and keratinocyte growth factor using thrombin protease
[0152] In order to separate bone morphogenetic protein 2 from calretinin 2 thrombin-bone morphogenetic protein 2 protein (hereinafter, the same experiment was performed in the case of calretinin 2 thrombin-keratinocyte growth factor 1 protein), 5 μl of thrombin protease was added and reacted at 22°C for one day, and then confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis ( Fig.26 , Fig.28 ). The results confirmed that the calpain tag and bone morphogenetic protein 2 fusion protein can be easily separated using thrombin protease.
[0153] Example 6. Separation of horseradish peroxidase and glucagon-like peptide 1 using calpain tag
[0154] 6-1. Purification of horseradish peroxidase-tobacco etch virus calcein 2 or horseradish peroxidase-thrombin calcein 2 and glucagon-like peptide 1-tobacco etch virus calcein 2
[0155] After the genes of horseradish peroxidase (SEQ ID NO: 18) and glucagon-like peptide 1 (SEQ ID NO: 19) were synthesized at Bioneer, they were cloned in tobacco etch virus muscle calpain 2 and thrombin muscle calpain 2 vectors, and then transformed into BL21 cells and coated on agar medium containing ampicillin. After the colonies grown in the agar plate medium were inoculated in 5 ml of LB medium containing ampicillin (50 μg / ml), they were mixed and cultured at a temperature of 37°C at a speed of 200 rpm for one day, and then mixed with glycerol at a ratio of 1:1 to prepare 1 ml of raw materials and stored in a quick freezer at -80°C. 100 μl of raw materials were inoculated in 30 ml of LB medium containing ampicillin (50 μg / ml), mixed and cultured at a temperature of 37°C at a speed of 200 rpm for one day, and then transferred into 1 L of LB medium containing ampicillin (50 μg / ml) and cultured to OD = 0.6. After that, add 1mM isopropyl-β-d-thiogalactoside and culture at 200rpm for one day at 17°C. Centrifuge at 4000rpm for 20 minutes at 4°C, remove all supernatants except the precipitated cells, and suspend with lysis buffer (20mM Tris (pH 8.0), 300mM NaCl and 10mM imidazole). After being stored at -80°C for one day, take out and completely dissolve, dissolve 10mg of phenylmethanesulfonyl fluoride in 1ml of dimethyl sulfoxide, and add 1ml to the dissolved Escherichia coli. After dissolving the Escherichia coli with a sonicator, centrifuge at 13000rpm for 1 hour at 4°C. Add 20mM CaCl2 to the supernatant and react at 4°C for 1 hour. After that, centrifuge at 5000rpm for 30 minutes. The supernatant was removed, and ethylenediaminetetraacetic acid was added to the precipitate and suspended to obtain horseradish peroxidase-tobacco etch virus muscle calcein 2 and horseradish peroxidase-thrombin muscle calcein 2 and glucagon-like peptide 1-tobacco etch virus muscle calcein 2 proteins ( Fig.29 , Fig.31 ).
[0156] 6-2. Separation of horseradish peroxidase and glucagon-like peptide 1 using tobacco etch virus protease
[0157] In order to separate horseradish peroxidase from horseradish peroxidase-tobacco etch virus calcein 2 protein (hereinafter, the same experiment was performed in the case of glucagon-like peptide 1-tobacco etch virus calcein 2 protein), 2 μl of tobacco etch virus protease (Genscript, USA) was added and reacted at 30°C for one day, and then confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis ( Fig.30 , Fig.32The results confirmed that the calcein tag and horseradish peroxidase fusion protein and the calcein tag and glucagon-like peptide 1 hydraulic protein can be easily separated using tobacco etch virus protease.
[0158] Example 7. Separation of epidermal growth factor and keratinocyte growth factor 1 using calpain tag
[0159] 7-1. Purification of calpain 1-Ssp DNA-epidermal growth factor and calpain 2-Ssp DNA-keratinocyte growth factor 1
[0160] After synthesizing the genes of epidermal growth factor (SEQ ID NO: 12) and keratinocyte growth factor 1 (SEQ ID NO: 13) at Bioneer, calpain 1-Ssp DNA and calpain 2-Ssp DNA vectors were cloned, converted to BL21 cells, and then coated on agar medium containing ampicillin. After the colonies grown in the agar plate medium were inoculated in 5 ml of LB medium containing ampicillin (50 μg / ml), mixed and cultured at 200 rpm for one day at 37°C, mixed with glycerol at a ratio of 1:1, 1 ml of raw materials were prepared and stored in a quick freezer at -80°C. 100 μl of raw materials were inoculated in 30 ml of LB medium containing ampicillin (50 μg / ml), mixed and cultured at 200 rpm for one day at 37°C, and then transferred into 1 L of LB medium containing ampicillin (50 μg / ml) and cultured to OD = 0.6. After that, add 1mM isopropyl-β-d-thiogalactoside and culture at 200rpm for one day at 17°C. Centrifuge at 4000rpm for 20 minutes at 4°C, remove all supernatants except the precipitated cells, and suspend with lysis buffer (20mM Tris (pH 8.0), 300mM NaCl and 10mM imidazole). After being stored at -80°C for one day, take out and completely dissolve, dissolve 10mg of phenylmethanesulfonyl fluoride in 1ml of dimethyl sulfoxide, and add 1ml to the dissolved Escherichia coli. After dissolving the Escherichia coli with a sonicator, centrifuge at 13000rpm for 1 hour at 4°C. Add 20mM CaCl2 to the supernatant and react at 4°C for 1 hour. After that, centrifuge at 5000rpm for 30 minutes. The supernatant was removed, and EDTA was added to the precipitate and suspended to obtain calretinin 1-SspDna-epidermal growth factor and calretinin 2-SspDna-keratinocyte growth factor 1 proteins ( Fig.33 , Fig.35 ).
[0161] 7-2. Separation of epidermal growth factor and keratinocyte growth factor 1 by pH value
[0162] In order to separate epidermal growth factor from calretinin 1-Ssp DNA-epidermal growth factor protein (hereinafter, the same experiment was performed in the case of calretinin 2-Ssp DNA-keratinocyte growth factor 1 protein), 20 mM hydroxyethylpiperazine ethanesulfonic acid (HEPES) pH 6.5, 500 mM NaCl buffer was reacted at room temperature for one day, and then confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis ( Fig.34 , Fig.36 ). The results confirmed that the calretinin tag and epidermal growth factor fusion protein can be easily separated by pH value.
[0163] Example 8. Separation of epidermal growth factor and bone morphogenetic protein 2 using calpain tag
[0164] 8-1. Purification of epidermal growth factor-GyrA-calretinin 1 and bone morphogenetic protein 2-GyrA-calretinin 2
[0165] After the genes of epidermal growth factor (SEQ ID NO: 12) and bone morphogenetic protein 2 (SEQ ID NO: 16) were synthesized by Bioneer, they were cloned in GyrA-calretinin 1 and GyrA-calretinin 2 vectors, transformed into BL21 cells and plated on agar medium containing ampicillin.
[0166] After the colonies grown in the agar plate medium were inoculated in 5 ml of LB medium containing ampicillin (50 μg / ml), mixed and cultured at 200 rpm for one day at a temperature of 37°C, mixed with glycerol at a ratio of 1:1, 1 ml of raw material was prepared and stored in a quick freezer at -80°C. 100 μl of raw material was inoculated in 30 ml of LB medium containing ampicillin (50 μg / ml), mixed and cultured at 200 rpm for one day at a temperature of 37°C, and then moved into 1 L of LB medium containing ampicillin (50 μg / ml) and cultured to OD = 0.6. Afterwards, 1 mM of isopropyl-β-d-thiogalactoside was added and cultured at 200 rpm for one day at a temperature of 17°C. Centrifuge at 4000 rpm for 20 minutes at 4°C, remove all supernatant except precipitated cells, and suspend with lysis buffer (20 mM Tris (pH 8.0), 300 mM NaCl, and 10 mM imidazole). After storing at -80°C for one day, take out and completely dissolve, dissolve 10 mg of phenylmethanesulfonyl fluoride in 1 ml of dimethyl sulfoxide, and add 1 ml to the dissolved Escherichia coli. After dissolving the Escherichia coli using a sonicator, centrifuge at 13000 rpm for 1 hour at 4°C. Add 20 mM CaCl2 to the supernatant and react at 4°C for 1 hour. Thereafter, centrifuge at 5000 rpm for 30 minutes. Remove the supernatant, add ethylenediaminetetraacetic acid to the precipitate and suspend it to obtain epidermal growth factor-GyrA-muscle calretinin 1 and bone morphogenetic protein 2-GyrA-muscle calretinin 2 proteins ( Fig.37 , Fig.39 ).
[0167] 8-2. Separation of epidermal growth factor and bone morphogenetic protein 2 using dithiothreitol
[0168] In order to separate epidermal growth factor from epidermal growth factor-GyrA-calretinin 1 protein (hereinafter, the same experiment was performed in the case of bone morphogenetic protein 2-GyrA-calretinin 2 protein), 20 mM hydroxyethylpiperazineethanesulfonic acid pH 8.5, 500 mM NaCl, 40 mM dithiothreitol buffer was reacted at room temperature for one day, and then sodium dodecyl sulfate-polyacrylamide gel electrophoresis was used to confirm ( Fig.38 , Fig.40 ). The results confirmed that the calretinin tag and epidermal growth factor fusion protein can be easily separated using dithiothreitol.
[0169] The above details the identified parts of the present invention. Such specific description is only a preferred embodiment, and the scope of the present invention is not limited thereto. It is obvious to those skilled in the art. Therefore, the scope of the present invention is defined by the scope of the invention claims and their equivalent technical solutions. <110> Korea Ceramic Technology Institute <120> Expression and purification of proteins using calpain tag <130> OP-2020-0010-KR <150> KR 10-2019-0040241 <151> 2019-04-05 <160> 25 <170> KopatentIn 2.0 <210> 1 <211> 362 <212> PRT <213> Artificial Sequence <220> <223> CSQ1 <400> 1 Gln Glu Gly Leu Asp Phe Pro Glu Tyr Asp Gly Val Asp Arg Val Ile 1 5 10 15 Asn Val Asn Ala Lys Asn Tyr Lys Asn Val Phe Lys Lys Tyr Glu Val 20 25 30 Leu Ala Leu Leu Tyr His Glu Pro Pro Glu Asp Asp Lys Ala Ser Gln 35 40 45 Arg Gln Phe Glu Met Glu Glu Leu Ile Leu Glu Leu Ala Ala Gln Val 50 55 60 Leu Glu Asp Lys Gly Val Gly Phe Gly Leu Val Asp Ser Glu Lys Asp 65 70 75 80 Ala Ala Val Ala Lys Lys Leu Gly Leu Thr Glu Val Asp Ser Met Tyr 85 90 95 Val Phe Lys Gly Asp Glu Val Ile Glu Tyr Asp Gly Glu Phe Ser Ala 100 105 110 Asp Thr Ile Val Glu Phe Leu Leu Asp Val Leu Glu Asp Pro Val Glu 115 120 125 Leu Ile Glu Gly Glu Arg Glu Leu Gln Ala Phe Glu Asn Ile Glu Asp 130 135 140 Glu Ile Lys Leu Ile Gly Tyr Phe Lys Ser Lys Asp Ser Glu His Tyr 145 150 155 160 Lys Ala Phe Glu Asp Ala Ala Glu Glu Phe His Pro Tyr Ile Pro Phe 165 170 175 Phe Ala Thr Phe Asp Ser Lys Val Ala Lys Lys Leu Thr Leu Lys Leu 180 185 190 Asn Glu Ile Asp Phe Tyr Glu Ala Phe Met Glu Glu Pro Val Thr Ile 195 200 205 Pro Asp Lys Pro Asn Ser Glu Glu Glu Ile Val Asn Phe Val Glu Glu 210 215 220 His Arg Arg Ser Thr Leu Arg Lys Leu Lys Pro Glu Ser Met Tyr Glu 225 230 235 240 Thr Trp Glu Asp Asp Met Asp Gly Ile His Ile Val Ala Phe Ala Glu 245 250 255 Glu Ala Asp Pro Asp Gly Phe Glu Phe Leu Glu Thr Leu Lys Ala Val 260 265 270 Ala Gln Asp Asn Thr Glu Asn Pro Asp Leu Ser Ile Ile Trp Ile Asp 275 280 285 Pro Asp Asp Phe Pro Leu Leu Val Pro Tyr Trp Glu Lys Thr Phe Asp 290 295 300 Ile Asp Leu Ser Ala Pro Gln Ile Gly Val Val Asn Val Thr Asp Ala 305 310 315 320 Asp Ser Val Trp Met Glu Met Asp Asp Glu Glu Asp Leu Pro Ser Ala 325 330 335 Glu Glu Leu Glu Asp Trp Leu Glu Asp Val Leu Glu Gly Glu Ile Asn 340 345 350 Thr Glu Asp Asp Asp Asp Asp Asp Asp Asp 355 360 <210> 2 <211> 380 <212> PRT <213> Artificial Sequence <220> <223> CSQ2 <400> 2 Glu Glu Gly Leu Asn Phe Pro Thr Tyr Asp Gly Lys Asp Arg Val Val 1 5 10 15 Ser Leu Ser Glu Lys Asn Phe Lys Gln Val Leu Lys Lys Tyr Asp Leu 20 25 30 Leu Cys Leu Tyr Tyr His Glu Pro Val Ser Ser Asp Lys Val Thr Pro 35 40 45 Lys Gln Phe Gln Leu Lys Glu Ile Val Leu Glu Leu Val Ala Gln Val 50 55 60 Leu Glu His Lys Ala Ile Gly Phe Val Met Val Asp Ala Lys Lys Glu 65 70 75 80 Ala Lys Leu Ala Lys Lys Leu Gly Phe Asp Glu Glu Gly Ser Leu Tyr 85 90 95 Ile Leu Lys Gly Asp Arg Thr Ile Glu Phe Asp Gly Glu Phe Ala Ala 100 105 110 Asp Val Leu Val Glu Phe Leu Leu Asp Leu Ile Glu Asp Pro Val Glu 115 120 125 Island Island Ser Ser Lys Leu Glu Val Gln Ala Phe Glu Arg Ile Glu Asp 130 135 140 Tyr Ile Lys Leu Ile Gly Phe Phe Lys Ser Glu Asp Ser Glu Tyr Tyr 145 150 155 160 Lys Ala Phe Glu Glu Ala Ala Glu His Phe Gln Pro Tyr Ile Lys Phe 165 170 175 Phe Ala Thr Phe Asp Lys Gly Val Ala Lys Lys Leu Ser Leu Lys Met 180 185 190 Asn Glu Val Asp Phe Tyr Glu Pro Phe Met Asp Glu Pro Ile Ala Ile 195 200 205 Pro Asn Lys Pro Tyr Thr Glu Glu Glu Leu Val Glu Phe Val Lys Glu 210 215 220 His Gln Arg Pro Thr Leu Arg Arg Leu Arg Pro Glu Glu Met Phe Glu 225 230 235 240 Thr Trp Glu Asp Asp Leu Asn Gly Ile His Ile Val Ala Phe Ala Glu 245 250 255 Lys Ser Asp Pro Asp Gly Tyr Glu Phe Leu Glu Ile Leu Lys Gln Val 260 265 270 Ala Arg Asp Asn Thr Asp Asn Pro Asp Leu Ser Ile Leu Trp Ile Asp 275 280 285 Pro Asp Asp Phe Pro Leu Leu Val Ala Tyr Trp Glu Lys Thr Phe Lys 290 295 300 Ile Asp Leu Phe Arg Pro Gln Ile Gly Val Val Asn Val Thr Asp Ala 305 310 315 320 Asp Ser Val Trp Met Glu Ile Pro Asp Asp Asp Asp Leu Pro Thr Here 325 330 335 Glu Glu Leu Glu Asp Trp Ile Glu Asp Val Leu Ser Gly Lys Ile Asn 340 345 350 Thr Glu Asp Asp Asp Glu Asp Asp Asp Asp Asp Asp Asn Ser Asp Glu 355 360 365 Glu Asp Asn Asp Asp Ser Asp Asp Asp Asp Asp Glu 370 375 380 <210> 3 <211> 1086 <212> DNA <213> Artificial Sequence <220> <223> CSQ1 <400> 3 caggaagggc tggacttccc tgagtacgat ggtgtggacc gtgtgatcaa tgtcaatgca 60 aagaactaca agaatgtgtt caagaagtat gaggtgctgg cactcctcta ccatgaaccc 120 cccgaggatg acaaggcctc acaaagacaa tttgagatgg aggagctgat cctggagtta 180 gcagcccaag tcctagaaga caagggtgtt ggcttcgggc tggtagactc tgagaaggat 240 gcagctgtgg ccaagaaact aggcctaact gaagtggaca gcatgtatgt attcaaggga 300 gatgaagtca ttgagtacga tggcgagttt tctgctgaca ccatcgtgga gtttctgctt 360 gatgtcctag aggaccctgt ggaattgatt gaaggtgaac gagagctgca ggcgtttgag 420 aatattgagg atgagatcaa actcattggc tacttcaaga gcaaagactc agagcattac 480 aaagccttcg aggatgcagc tgaggagttt catccctaca tccccttctt cgccaccttc 540 gacagcaagg tggcaaagaa gctgaccctg aagctgaatg agattgattt ctacgaggcc 600 ttcatggaag agcctgtgac catcccagac aagcccaata gcgaagagga gattgtcaac 660 ttcgtggagg agcacaggag atcaaccctg aggaaactga agccggagag tatgtatgag 720 acctgggagg atgatatgga tggaatccac attgtggcct tcgcagagga agctgatcct 780 gatggtttcg agttcttaga gactctcaag gctgtggccc aagataacac tgaaaaccca 840 gatcttagca tcatctggat tgaccctgat gacttccccc tgctggtccc atactgggag 900 aagacgtttg acatcgactt gtcagcccca caaataggag tcgtcaatgt tactgatgcg 960 gatagcgtat ggatggaaat ggacgatgag gaggacctgc cttctgctga ggagctggag 1020 gactggctgg agatgtcct ggagggcgag atcaacacag aggacgatga cgatgatgat 1080 Cave 1086 <210> 4 <211> 1143 <212> DNA <213> Artificial Sequence <220> <223> CSQ2 <400> 4 gaagaggggc ttaatttccc cacatatgat gggaaggacc gagtggtaag tctttccgag 60 aagaacttca agcaggtttt aaagaaatat gacttgcttt gcctctacta ccatgagccg 120 gtgtcttcag ataaggtcac gccaaaacag ttccaactga aagaaatcgt gcttgagctt 180 gtggcccagg tccttgaaca taaagctata ggctttgtga tggtggatgc caagaaagaa 240 gccaagcttg ccaagaaact gggttttgat gaagaaggaa gcctgtatat tcttaagggt 300 gatcgcacaa tagagtttga tggcgagttt gcagctgatg tcttggtgga gttcctcttg 360 gatctaattg aagacccagt ggagatcatc agcagcaaac tggaagtcca agccttcgaa 420 cgcattgaag actacatcaa actcattggc ttttcaaga gtgaggactc agaatactac 480 aaggctttg aagaagcagc tgaacacttc cagccttaca tcaaattctt tgccaccttt 540 gacaaagggg ttgcaaagaa attatctttg aagatgaatg aggttgactt ctatgagcca tttatggatg agcccattgc catccccaac aaaccttaca cagaagagga gctggtggag tttgtgaagg aacaccaaag acccactcta cgtcgcctgc gcccagaaga aatgtttgaa acatgggaag atgatttgaa tgggatccac attgtggcct ttgcagagaa gagtgatcca gatggctacg aattcctgga gatcctgaaa caggttgccc gggacaatac tgacaacccc gatctgagca tcctgtggat cgacccggac gactttcctc tgctcgttgc ctactgggag 900 aagactttca agattgacct attcaggcca cagattgggg tggtgaatgt cacagatgct gacagtgtct ggatggagat tccagatgat gacgatcttc caactgctga ggagctggag gactggattg aggatgtgct ttctggaaag ataaacactg aagatgatga tgaagatgat gatgatgatg ataattctga tgaagaggat aatgatgaca gtgatgacga tgatgatga tag <210> 5 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> TEV <400> 5 Glu Asn Leu Tyr Phe Gln Gly 1 5 <210> 6 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Thrombin <400> 6 Leu Val Pro Arg Gly Ser 1 5 <210> 7 <211> 431 <212> PRT <213> Artificial Sequence <220> <223> Ssp Dna <400> 7 Gly Cys Ile Ser Gly Asp Ser Leu Ile Ser Leu Ala Ser Thr Gly Lys 1 5 10 15 Arg Val Ser Ile Lys Asp Leu Leu Asp Glu Lys Asp Phe Glu Ile Trp 20 25 30 Ala Ile Asn Glu Gln Thr Met Lys Leu Glu Ser Ala Lys Val Ser Arg 35 40 45 Val Phe Cys Thr Gly Lys Lys Leu Val Tyr Ile Leu Lys Thr Arg Leu 50 55 60 Gly Arg Thr Ile Lys Ala Thr Ala Asn His Arg Phe Leu Thr Ile Asp 65 70 75 80 Gly Trp Lys Arg Leu Asp Glu Leu Ser Leu Lys Glu His Ile Ala Leu 85 90 95 Pro Arg Lys Leu Glu Ser Ser Ser Leu Gln Leu Met Ser Asp Glu Glu 100 105 110 Leu Gly Leu Leu Gly His Leu Ile Gly Asp Gly Cys Thr Leu Pro Arg 115 120 125 His Ala Ile Gln Tyr Thr Ser Asn Lys Ile Glu Leu Ala Glu Lys Val 130 135 140 Val Glu Leu Ala Lys Ala Val Phe Gly Asp Gln Ile Asn Pro Arg Ile 145 150 155 160 Ser Gln Glu Arg Gln Trp Tyr Gln Val Tyr Ile Pro Ala Ser Tyr Arg 165 170 175 Leu Thr His Asn Lys Lys Asn Pro Ile Thr Lys Trp Leu Glu Asn Leu 180 185 190 Asp Val Phe Gly Leu Arg Ser Tyr Glu Lys Phe Val Pro Asn Gln Val 195 200 205 Phe Glu Gln Pro Gln Arg Ala Ile Ala Ile Phe Leu Arg His Leu Trp 210 215 220 Ser Thr Asp Gly Cys Val Lys Leu Ile Val Glu Lys Ser Ser Arg Pro 225 230 235 240 Val Ala Tyr Tyr Ala Thr Ser Ser Glu Lys Leu Ala Lys Asp Val Gln 245 250 255 Ser Leu Leu Leu Lys Leu Gly Ile Asn Ala Arg Leu Ser Lys Ile Ser 260 265 270 Gln Asn Gly Lys Gly Arg Asp Asn Tyr His Val Thr Ile Thr Gly Gln 275 280 285 Ala Asp Leu Gln Ile Phe Val Asp Gln Ile Gly Ala Val Asp Lys Asp 290 295 300 Lys Gln Ala Ser Val Glu Glu Ile Lys Thr His Ile Ala Gln His Gln 305 310 315 320 Ala Asn Thr Asn Arg Asp Val Ile Pro Lys Gln Ile Trp Lys Thr Tyr 325 330 335 Val Leu Pro Gln Ile Gln Ile Lys Gly Ile Thr Thr Arg Asp Leu Gln 340 345 350 Met Arg Leu Gly Asn Ala Tyr Cys Gly Thr Ala Leu Tyr Lys His Asn 355 360 365 Leu Ser Arg Glu Arg Ala Ala Lys Ile Ala Thr Ile Thr Gln Ser Pro 370 375 380 Glu Ile Glu Lys Leu Ser Gln Ser Asp Ile Tyr Trp Asp Ser Ile Val 385 390 395 400 Ser Ile Thr Glu Thr Gly Val Glu Glu Val Phe Asp Leu Thr Val Pro 405 410 415 Gly Pro His Asn Phe Val Ala Asn Asp Ile Ile Val His Asn Ser 420 425 430 <210> 8 <211> 200 <212> PRT <213> Artificial Sequence <220> <223> GyrA <400> 8 Tyr Cys Ile Thr Gly Asp Ala Leu Val Ala Leu Pro Glu Gly Glu Ser 1 5 10 15 Val Arg Ile Ala Asp Ile Val Pro Gly Ala Arg Pro Asn Ser Asp Asn 20 25 30 Ala Ile Asp Leu Lys Val Leu Asp Arg His Gly Asn Pro Val Leu Ala 35 40 45 Asp Arg Leu Phe His Ser Gly Glu His Pro Val Tyr Thr Val Arg Thr 50 55 60 Val Glu Gly Leu Arg Val Thr Gly Thr Ala Asn His Pro Leu Leu Cys 65 70 75 80 Leu Val Asp Val Ala Gly Val Pro Thr Leu Leu Trp Lys Leu Ile Asp 85 90 95 Glu Ile Lys Pro Gly Asp Tyr Ala Val Ile Gln Arg Ser Ala Phe Ser 100 105 110 Val Asp Cys Ala Gly Phe Ala Arg Gly Lys Pro Glu Phe Ala Pro Thr 115 120 125 Thr Tyr Thr Val Gly Val Pro Gly Leu Val Arg Phe Leu Glu Ala His 130 135 140 His Arg Asp Pro Asp Ala Gln Ala Ile Ala Asp Glu Leu Thr Asp Gly 145 150 155 160 Arg Phe Tyr Tyr Ala Lys Val Ala Ser Val Thr Asp Ala Gly Val Gln 165 170 175 Pro Val Tyr Ser Leu Arg Val Asp Thr Ala Asp His Ala Phe Ile Thr 180 185 190 Asn Gly Phe Val Ser His Asn Thr 195 200 <210> 9 <211> 91 <212> PRT <213> Artificial Sequence <220> <223> EBD14 <400> 9 Glu Val Pro Gln Leu Thr Asp Leu Ser Phe Val Asp Ile Thr Asp Ser 1 5 10 15 Ser Ile Gly Leu Arg Trp Val Gln Cys Gln Cys Ala Gly Ile Ile Gly 20 25 30 Tyr Arg Ile Thr Val Val Ala Ala Gly Glu Gly Ile Pro Ile Phe Glu 35 40 45 Asp Phe Val Asp Pro Ala Cys Val Tyr Tyr Thr Val Thr Gly Leu Glu 50 55 60 Pro Gly Ile Asp Tyr Asp Ile Ser Val Ile Thr Leu Ile His Arg Ile 65 70 75 80 His Pro Asn Pro Thr Thr Leu Thr Gln Gln Thr 85 90 <210> 10 <211> 91 <212> PRT <213> Artificial Sequence <220> <223> EBD21 <400> 10 Glu Val Pro Gln Leu Thr Asp Leu Ser Phe Val Asp Met Thr Asp Ser 1 5 10 15 Ser Ile Gly Leu Arg Trp Val Gln Val Met Arg Met Gly Ile Ile Gly 20 25 30 Tyr Arg Ile Thr Val Val Ala Ala Gly Glu Gly Ile Pro Ile Phe Glu 35 40 45 Asp Phe Val Asp His Pro Ile Arg Tyr Tyr Thr Val Thr Gly Leu Glu 50 55 60 Pro Gly Ile Asp Tyr Asp Ile Ser Val Ile Thr Leu Ile Pro Trp Gln 65 70 75 80 Arg His Arg Pro Thr Thr Leu Thr Gln Gln Thr 85 90 <210> 11 <211> 91 <212> PRT <213> Artificial Sequence <220> <223> EBD26 <400> 11 Glu Val Pro Gln Leu Thr Asp Leu Ser Phe Val Asp Ile Thr Asp Ser 1 5 10 15 Ser Ile Gly Leu Arg Trp Arg Met Thr Cys Leu Cys Leu Ile Ile Gly 20 25 30 Tyr Arg Ile Thr Val Val Ala Ala Gly Glu Gly Ile Pro Ile Phe Glu 35 40 45 Asp Phe Val Asp Asp Pro Trp Thr Tyr Tyr Thr Val Thr Gly Leu Glu 50 55 60 Pro Gly Ile Asp Tyr Asp Ile Ser Val Ile Thr Leu Ile Thr Gln Lys 65 70 75 80 His Val Lys Pro Thr Thr Leu Thr Gln Gln Thr 85 90 <210> 12 <211> 53 <212> PRT <213> Artificial Sequence <220> <223> EGF <400> 12 Asn Ser Asp Ser Glu Cys Pro Leu Ser His Asp Gly Tyr Cys Leu His 1 5 10 15 Asp Gly Val Cys Met Tyr Ile Glu Ala Leu Asp Lys Tyr Ala Cys Asn 20 25 30 Cys Val Val Gly Tyr Ile Gly Glu Arg Cys Gln Tyr Arg Asp Leu Lys 35 40 45 Trp Trp Glu Leu Arg 50 <210> 13 <211> 164 <212> PRT <213> Artificial Sequence <220> <223> KGF1 <400> 13 Met Cys Asn Asp Met Thr Pro Glu Gln Met Ala Thr Asn Val Asn Cys 1 5 10 15 Ser Ser Pro Glu Arg His Thr Arg Ser Tyr Asp Tyr Met Glu Gly Gly 20 25 30 Asp Ile Arg Val Arg Arg Leu Phe Cys Arg Thr Gln Trp Tyr Leu Arg 35 40 45 Ile Asp Lys Arg Gly Lys Val Lys Gly Thr Gln Glu Met Lys Asn Asn 50 55 60 Tyr Asn Ile Met Glu Ile Arg Thr Val Ala Val Gly Ile Val Ala Ile 65 70 75 80 Lys Gly Val Glu Ser Glu Phe Tyr Leu Ala Met Asn Lys Glu Gly Lys 85 90 95 Leu Tyr Ala Lys Lys Glu Cys Asn Glu Asp Cys Asn Phe Lys Glu Leu 100 105 110 Ile Leu Glu Asn His Tyr Asn Thr Tyr Ala Ser Ala Lys Trp Thr His 115 120 125 Asn Gly Gly Glu Met Phe Val Ala Leu Asn Gln Lys Gly Ile Pro Val 130 135 140 Arg Gly Lys Lys Thr Lys Lys Glu Gln Lys Thr Ala His Phe Leu Pro 145 150 155 160 Met Ala Ile Thr <210> 14 <211> 147 <212> PRT <213> Artificial Sequence <220> <223> VEGF <400> 14 Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu 1 5 10 15 Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly 20 25 30 Gly Gly Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln 35 40 45 Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu 50 55 60 Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu 65 70 75 80 Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro 85 90 95 Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His 100 105 110 Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys 115 120 125 Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Lys Cys Asp Lys 130 135 140 Pro Arg Arg 145 <210> 15 <211> 146 <212> PRT <213> Artificial Sequence <220> <223> FGF2 <400> 15 Pro Ala Leu Pro Glu Asp Gly Gly Ser Gly Ala Phe Pro Pro Gly His 1 5 10 15 Phe Lys Asp Pro Lys Arg Leu Tyr Cys Lys Asn Gly Gly Phe Phe Leu 20 25 30 Arg Ile His Pro Asp Gly Arg Val Asp Gly Val Arg Glu Lys Ser Asp 35 40 45 Pro His Ile Lys Leu Gln Leu Gln Ala Glu Glu Arg Gly Val Val Ser 50 55 60 Ile Lys Gly Val Cys Ala Asn Arg Tyr Leu Ala Met Lys Glu Asp Gly 65 70 75 80 Arg Leu Leu Ala Ser Lys Cys Val Thr Asp Glu Cys Phe Phe Phe Glu 85 90 95 Arg Leu Glu Ser Asn Asn Tyr Asn Thr Tyr Arg Ser Arg Lys Tyr Thr 100 105 110 Ser Trp Tyr Val Ala Leu Lys Arg Thr Gly Gln Tyr Lys Leu Gly Ser 115 120 125 Lys Thr Gly Pro Gly Gln Lys Ala Ile Leu Phe Leu Pro Met Ser Ala 130 135 140 Lys Ser 145 <210> 16 <211> 115 <212> PRT <213> Artificial Sequence <220> <223> BMP2 <400> 16 Met Gln Ala Lys His Lys Gln Arg Lys Arg Leu Lys Ser Ser Cys Lys 1 5 10 15 Arg His Pro Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asn Asp Trp 20 25 30 Ile Val Ala Pro Pro Gly Tyr His Ala Phe Tyr Cys His Gly Glu Cys 35 40 45 Pro Phe Pro Leu Ala Asp His Leu Asn Ser Thr Asn His Ala Ile Val 50 55 60 Gln Thr Leu Val Asn Ser Val Asn Ser Lys Ile Pro Lys Ala Cys Cys 65 70 75 80 Val Pro Thr Glu Leu Ser Ala Ile Ser Met Leu Tyr Leu Asp Glu Asn 85 90 95 Glu Lys Val Val Leu Lys Asn Tyr Gln Asp Met Val Val Glu Gly Cys 100 105 110 Gly Cys Arg 115 <210> 17 <211> 113 <212> PRT <213> Artificial Sequence <220> <223> TGF <400> 17 Ala Leu Asp Thr Asn Tyr Cys Phe Ser Ser Thr Glu Lys Asn Cys Cys 1 5 10 15 Val Arg Gln Leu Tyr Ile Asp Phe Arg Lys Asp Leu Gly Trp Lys Trp 20 25 30 Ile His Glu Pro Lys Gly Tyr His Ala Asn Phe Cys Leu Gly Pro Cys 35 40 45 Pro Tyr Ile Trp Ser Leu Asp Thr Gln Tyr Ser Lys Val Leu Ala Leu 50 55 60 Tyr Asn Gln His Asn Pro Gly Ala Ser Ala Ala Pro Cys Cys Val Pro 65 70 75 80 Gln Ala Leu Glu Pro Leu Pro Ile Val Tyr Tyr Val Gly Arg Lys Pro 85 90 95 Lys Val Glu Gln Leu Ser Asn Met Ile Val Arg Ser Cys Lys Cys Ser 100 105 110 Arg <210> 18 <211> 323 <212> PRT <213> Artificial Sequence <220> <223> HRP <400> 18 Gln Leu Thr Pro Thr Phe Tyr Asp Asn Ser Cys Pro Asn Val Ser Asn 1 5 10 15 Ile Val Arg Asp Thr Ile Val Asn Glu Leu Arg Ser Asp Pro Arg Ile 20 25 30 Ala Ala Ser Ile Leu Arg Leu His Phe His Asp Cys Phe Val Asn Gly 35 40 45 Cys Asp Ala Ser Ile Leu Leu Asp Asn Thr Thr Ser Phe Arg Thr Glu 50 55 60 Lys Asp Ala Phe Gly Asn Ala Asn Ser Ala Arg Gly Phe Pro Val Ile 65 70 75 80 Asp Arg Met Lys Ala Ala Val Glu Ser Ala Cys Pro Arg Thr Val Ser 85 90 95 Cys Ala Asp Leu Leu Thr Ile Ala Ala Gln Gln Ser Val Thr Leu Ala 100 105 110 Gly Gly Pro Ser Trp Arg Val Pro Leu Gly Arg Arg Asp Ser Leu Gln 115 120 125 Ala Phe Leu Asp Leu Ala Asn Ala Asn Leu Pro Ala Pro Phe Phe Thr 130 135 140 Leu Pro Gln Leu Lys Asp Ser Phe Arg Asn Val Gly Leu Asn Arg Ser 145 150 155 160 Ser Asp Leu Val Ala Leu Ser Gly Gly His Thr Phe Gly Lys Asn Gln 165 170 175 Cys Arg Phe Ile Met Asp Arg Leu Tyr Asn Phe Ser Asn Thr Gly Leu 180 185 190 Pro Asp Pro Thr Leu Asn Thr Thr Tyr Leu Gln Thr Leu Arg Gly Leu 195 200 205 Cys Pro Leu Asn Gly Asn Leu Ser Ala Leu Val Asp Phe Asp Leu Arg 210 215 220 Thr Pro Thr Ile Phe Asp Asn Lys Tyr Tyr Val Asn Leu Glu Glu Gln 225 230 235 240 Lys Gly Leu Ile Gln Ser Asp Gln Glu Leu Phe Ser Ser Pro Asn Ala 245 250 255 Thr Asp Thr Ile Pro Leu Val Arg Ser Phe Ala Asn Ser Thr Gln Thr 260 265 270 Phe Phe Asn Ala Phe Val Glu Ala Met Asp Arg Met Gly Asn Ile Thr 275 280 285 Pro Leu Thr Gly Thr Gln Gly Gln Ile Arg Leu Asn Cys Arg Val Val 290 295 300 Asn Ser Asn Ser Leu Leu His Asp Met Val Glu Val Val Asp Phe Val 305 310 315 320 Ser Ser Met <210> 19 <211> 32 <212> PRT <213> Artificial Sequence <220> <223> GLP1 <400> 19 Ala Ala His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu 1 5 10 15 Glu Glu Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Ala 20 25 30 <210> 20 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> PRIMER <400> 20 aatggatccg aggtgcccca actcactgac 30 <210> 21 <211> 36 <212> DNA <213> Artificial Sequence <220> <223> PRIMER <400> 21 attctcgagt tacgtttgtt gtgtcagtgt agtagg 36 <210> 22 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> PRIMER <400> 22 aatggatcca actctgatag cgaatgcccg 30 <210> 23 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> PRIMER <400> 23 attctcgagt taacgcagtt cccaccattt 30 <210> 24 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> PRIMER <400> 24 cagcaagaca gcgatggatc c 21 <210> 25 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> PRIMER <400> 25 cgacttacag gtgatctcga g 21
Claims
1. An expression vector for expression, water solubilization and purification of a target protein, the expression vector comprising a nucleic acid encoding a fusion protein, the fusion protein consisting of: A calpain tag, a target protein, and a peptide degradable by a hydrolase, which is linked between the calpain tag and the target protein.
2. The expression vector according to claim 1, characterized in that The calpain tag is composed of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO:
2.
3. The expression vector according to claim 1, characterized in that The hydrolase-degradable peptide consists of an amino acid sequence selected from SEQ ID NO:5 to SEQ ID NO:
8.
4. The expression vector according to claim 1, characterized in that The target protein is selected from the group consisting of glycoproteins, growth factors, blood products, vaccines, hormones, enzymes and antibodies.
5. The expression vector according to claim 4, characterized in that The target protein is selected from interleukin 2, blood factor VII, blood factor VIII, blood factor IX, immunoglobulin, horseradish peroxidase, α-interferon, β-interferon, γ-interferon, colony stimulating factor, human fibronectin extra domain B, bone morphogenetic protein, fibroblast growth factor, vascular endothelial growth factor, nerve growth factor, epidermal growth factor, insulin growth factor, transforming growth factor-α and transforming growth factor-β, brain-derived neurotrophic factor, platelet-derived growth factor, placental growth factor, hepatocyte growth factor, keratinocyte growth factor, glucagon-like peptide-1, exendin, somatostatin, luteinizing hormone-releasing hormone, adrenocorticotropic hormone, growth hormone-releasing hormone, oxytocin, thymosin α -1, the group consisting of corticotropin-releasing factor, calcitonin, bivalirudin, vasopressin, phospholipase activating protein, insulin, tumor necrosis factor, follicle-stimulating hormone, thyroid-stimulating hormone, antidiuretic hormone, pigment hormone, parathyroid hormone, luteinizing hormone, calcitonin gene-related peptide, enkephalin, somatomedin, erythropoietin, hypothalamic secretory factor, prolactin, chronic gonadotropin, growth hormone-releasing peptide, thymic humoral factor, asparaginase, arginase, arginine deaminase, adenosine deaminase, superoxide dismutase, endotoxin enzyme, catalase, chymotrypsin, lipase, uricase, adenosine diphosphatase, tyrosinase, bilirubin oxidase, glucose oxidase, glucosidase, galactosidase, glucocerebrosidase and glucuronidase.
6. The expression vector according to claim 1, characterized in that The target protein is composed of an amino acid sequence selected from SEQ ID NO: 9 to SEQ ID NO:
19.
7. A transformed cell, characterized in that: Transformed using the expression vector of any one of claims 1 to 6, wherein the transformed cells do not include plant cells.
8. The transformed cell according to claim 7, characterized in that The above cells are Escherichia coli, Bacillus subtilis, Bacillus thuringiensis, Salmonella typhimurium, Serratia marcescens, Pseudomonas, yeast, insect cells, Chinese hamster ovary cell line, W138, BHK, COS-7, 293, HepG2, 3T3, RIN, and MDCK cell lines.
9. A method for expressing and purifying a target protein using a calpain tag, characterized in that: include: Step A), preparing the expression vector according to any one of claims 1 to 6; Step B), transducing the above expression vector into host cells to obtain transformants; Step C), expressing a fusion protein comprising a calpain tag and a target protein from the transformant; Step D), using calcium to precipitate the fusion protein comprising the calretinin tag and the target protein from the expressed transformant; as well as Step E), using a hydrolase to separate the target protein from the fusion protein.
